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Abbreviations and units 
AA    Amino acid 
AD    Alzheimer’s disease 
ADAM   a disintegrin and metalloprotease  
AICD   APP intracellular domain 
Aph-1   Anterior pharynx defective protein-1 
APLP   Amyloid precursor like protein 
APP   Amyloid precursor protein 
App0/0   Amyloid precursor protein knockout 
APPs   soluble APP 
Aβ    Amyloid beta peptide 
BACE   Beta site APP cleaving enzyme 
BCIP   5-bromo-4-chlor-indolyl-phosphate 
BP1   APP binding protein 1 
BSA   Bovine serum albumin 
Ca2+ATPase Calcium ATPase 
CCE   Capacitative calcium entry 
CPA   Cyclopiazonic acid 
CSF   Cerebrospinal fluid 
C-terminus  Carboxyl terminus 
CTFs   Carboxy terminal fragments 
DMEM   Dulbecco’s modified eagle’s medium 
Dox    Doxycycline 
DTT   Dithiothreitol 
EDTA   Ethylenediamine tetra aceticacid 
EOFAD   Early onset of familial Alzheimer’s disease 
ER    Endoplasmatic reticulum 
FAD   Familial Alzheimer’s disease 
FCCP   Carbonyl cyanide 4-trifluoro-methoxyphenylhydrazone 
FCS   Foetal calf serum 
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GSK   Glycogen synthase kinase 
H4 cells   Human neuroglioma cells 
HBSS   Hank’s basal salt solution 
Hek cells  Human embryonic kidney cells 
ICD    Intracellular domain 
IDE    Insulin degrading enzyme 
IP3    Inositol-1,4,5-triphosphate 
IP3R   Inositol-1,4,5-triphosphate receptor(s)   
KPI    Kunitz protease inhibitor 
LDL   Low density lipids 
MAP   Microtubule associated protein 
NaCN   Sodium cyanide 
NBT   Nitroblue tetrazolium chloride 
NFT   Neurofibrillary tangles 
NICD   Notch intracellular domain 
PAT   Protein interacting with APP tail 
PDL   poly-D-lysine 
PEN-2   Presenilin enhancer protein-2 
PHF   Paired helical fragment 
PiP2   Phosphatidyl inositol-4,5-biphosphate 
PLC   Phospholipase C 
PMCA   Plasmamembrane calcium ATPase 
PS1   Presenilin 1 
PS2   Presenilin 2 
ROCC   Receptor operated calcium channels 
ROS   Reactive oxygen species 
RYR   Ryanodine receptor 
sAPPα   soluble alpha APP ectodomain 
sAPPβ   soluble beta APP ectodomain 
SDS   Sodium dodecyl sulphate 
SERCA   Sarcoendoplasmic reticulum calcium ATPase 
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SOCC   Store operated calcium channel 
SR    Sarcoendoplasmic reticulum 
TACE   Tumor necrosis factor alpha converting enzyme 
TBS   Tris buffered saline 
TGN   trans-Golgi network 
TMPD   2,3,5,6-tetramethyl-p-phenylenediamine 
TNF   Tumor necrosis factor     
VOCC   Voltage operated calcium channels 
VSV tag   Vesicular somatitis virus tag 
α-secretase  alpha secretase 
β-secretase  beta secretase 
γ-secretase  gamma secretase 
ε-secretase  epsilon secretase 
 
Units 
µF    microfarad 
µg    microgram 
µl    microlitre 
µm    micrometer 
µM    micromolar 
bp    base pair   
cm    centimeter 
hrs    hours 
kb    kilobase 
kDa    kilodalton 
kV    kilovolt 
M    molar (= moles per liter) 
mA    milliampere 
mg    milligram 
MHz   megahertz 
min    minute 
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ml    milliliter 
mm    millimeter 
mM    millimolar 
ng    nanogram 
nm    nanometer 
oC    degree Celsius 
pmol   picomole 
rpm    revolutions per minute 
v/v    volume per volume 
w/v    weight per volume 
x g    relative centrifugal force 
%    percent 
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1 Summary 
The work presented in this thesis is aimed to contribute to the understanding of 
the physiological role of APP and its underlying mechanism controlling the Ca2+ 
homeostasis. In addition, it aims to understand the pathophysiological role of 
Amyloid precursor protein (APP) and its cleavage products in Alzheimer’s 
disease (AD) particularly focussing on the disturbances in normal Ca2+ 
homeostasis resulting from altered APP processing. A central hypothesis to the 
pathogenesis of AD is that the accumulation of amyloid-β peptide (Aβ) and/or 
Aβ-containing plaques play an important role in the development of the 
disease. Mutations in APP, Presenilin 1 (PS1), or Presenilin 2 (PS2) are linked 
to the inherited forms of the disease and result in an increased production of 
Aβ, particularly of the Aβ42 isoform. Most mutations in APP, PS1, or PS2 that 
are associated with Familial Alzheimer’s Disease (FAD) alter the γ-secretase 
cleavage, resulting in increased levels of Aβ42 species and affecting the 
generation of corresponding C-terminal fragments (CTFs), for instance, the 
APP intracellular domain (AICD). Recently, several studies have indicated that 
not only altered production of Aβ42 affect neuronal survival, but also the CTFs, 
predominantly AICD, have a critical pathophysiological role by modulating 
neuronal Ca2+ homeostasis. 
In the present study, the mechanism by which APP or its cleavage products 
maintains Ca2+ homeostasis, is investigated in more detail by analyzing free 
cytosolic Ca2+ concentration in different cell types under various experimental 
conditions. In all the cell types analyzed, it was consistently observed that the 
loss of γ-secretase derived APP C-terminal fragment, AICD, enhances the 
basal resting cytosolic Ca2+ levels and reduce intracellular endoplasmatic 
reticulum (ER) Ca2+ storage. The correlation of enhanced resting Ca2+ and 
reduced ER Ca2+ storage strongly indicate an alteration of the mechanisms 
involved in Ca2+ buffering by the ER.  
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One of the most important mechanisms involved in the removal of Ca2+ from 
cytosol, to maintain the resting Ca2+ concentration, is mediated by Calcium 
ATPases (Ca2+ATPases) that pumps Ca2+ from the cytosol into the ER lumen. 
This process is strongly ATP dependent. The mitochondrial membrane 
potential (or proton motive force) is the central bioenergetic parameter that 
controls ATP synthesis, therefore both mitochondrial membrane potential using 
rhodamine-123 fluorescent probe and ATP production using a bioluminescent 
assay were determined. Cells lacking AICD fragments were found to exhibit a 
lower ATP generation and a higher mitochondrial membrane potential. These 
results indicate a dysfunction of ATP synthase as a consequence of loss of 
AICD. Indeed blockade of mitochondrial ATP synthase by oligomycin in AICD 
expressing cells led to the similar alterations in Ca2+ storage as in the cells 
lacking AICD. On the other hand, administration of mitochondrial substrates on 
AICD non-expressing cells exhibited responses analogous to AICD expressing 
cells. Collectively, our data suggest that AICD is critically involved in 
mitochondrial ATP synthesis through a γ-secretase dependent signalling 
pathway controlling ATP dependent cellular mechanisms such as the cellular 
Ca2+ storage.  
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2 Introduction 
2.1 Alzheimer’s disease  
Age related impairment of memory and of cognitive functions, defined as 
‘dementia’, is a brain disorder that seriously affects a person’s capability to carry 
out day to day activities. The most common form of dementia is ‘Alzheimer’s 
disease’, accounting for 60-80% of all dementia cases. This involves the part of 
brain that control thought, memory and language. AD affects 7-10% of individuals 
older than 65 years and up to 40% of persons older than 80 years (Evans et al., 
1989). The word “Alzheimer’s” is named after a German doctor, Dr. Alois 
Alzheimer. In 1907, he described this condition in a 51 year old woman who died 
of an unusual mental illness showing impaired memory, orientation problems and 
disturbed behaviour  (Alzheimer, 1907; Alzheimer et al., 1995). In the woman’s 
brain tissue he found abnormal clumps (now called neuritic or amyloid plaques) 
and tangled bundles of fibres (now called neurofibrillary tangles) (Fig 2.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 2.1:  Photograph of an original section of the first case described by Alois Alzheimer in 1907 
(from the archives of Dept. of Neuropathology, Munich). Photograph shows a neurofibrillary 
tangle and the neuritic plaques.  
 
 
Neuritic 
plaques
Neurofibrillary 
tangle
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Today, these plaques and tangles in the brain are considered signs of 
Alzheimer’s disease. Early and objective diagnosis is however still impossible 
and only definitive by pathological diagnosis of the brain postmortem. 
 
2.2 Pathology of Alzheimer’s disease 
Clinically, the disease is initially characterized by subtle short-term memory 
problems and orientation disturbances. As the disease progresses, all higher 
cognitive functions become affected and the patients become completely 
dependent. The pathology of AD is restricted to the central nervous system and 
is pathologically characterized by the presence of extracellular senile amyloid 
plaques and intracellular neurofibrillary tangles. In addition, amyloid deposits in 
the walls of cerebral blood vessels (cerebral amyloid angiopathy), loss of 
neuronal cell bodies and synapses, as well as severe reactive astrogliosis can be 
observed. 
 
2.2.1 Amyloid Plaques 
Amyloid plaques are complex lesions composed of diverse amyloid peptides and 
associated molecules, degenerating neuronal processes and reactive glia 
(Dickson, 1997). Two types of extracellular amyloid deposits have been 
identified: neuritic and non-neuritic (diffuse plaques). The neuritic plaques, which 
measure 20-200 µm across, consist principally of an amyloid core surrounded by 
swollen abnormal processes, called dystrophic neurites. Biochemically, the most 
important component of the amyloid core is Aβ, a 4 kDa peptide proteolytically 
derived from the 110-130 kDa APP (Glenner and Wong, 1984; Robakis et al., 
1987). Although Aβ is the major component of the amyloid deposits, other 
molecules are also known to be associated with these deposits i.e. α1-
antichymotrypsin, α2-macroglobulin, LDL-receptors related protein, acetylcholine 
esterase, laminin, glycosaminoglycans, and the apolipoproteins.(Strittmatter and 
Roses, 1995; Bronfman et al., 1996; Van Uden et al., 2000). On the other hand, 
non-neuritic plaques differ from neuritic plaques, in that, they do not contain an 
                                                                                                              Introduction               
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amyloid core and, at most, only few or no neuritic processes. While both plaque 
types are found in the brains of non-demented old people, large number of 
neuritic plaques are only found in the brains of AD patients. Amyloid plaques are 
particularly abundant in the neocortex, the hippocampus, and the amygdale 
regions of the brain. 
 
2.2.2 Neurofibrillary tangles  
The second pathological hallmark in brain of AD patients is intracellular 
neurofibrillary tangles (NFT). The tangles consist mainly of paired helical 
filaments (PHF) of about 10 nm which are wound into helices. Some are straight 
filaments of about 15 nm interspersed with PHF. Extensive biochemical and 
immunological studies of these poorly soluble filaments demonstrated that the 
principal and probably the sole protein subunit is hyperphosphorylated protein 
Tau, a major neuronal microtubule-associated protein (MAP) (Kosik et al., 1986; 
Nukina and Ihara, 1986; Wood et al., 1986; Grundke-Iqbal et al., 1986a; 
Grundke-Iqbal et al., 1986b; Wischik et al., 1988; Lee et al., 1991). 
In AD, about 95% of Tau filaments are in the form of  PHF, while the remainder 
are straight filaments  (Spillantini and Goedert, 1998). In normal brain, Tau 
protein binds to and stabilize microtubules, in contrast to PHF where Tau is 
unable to bind to microtubules.  
 
2.3 Genetics of Alzheimer’s disease 
Most cases of AD are sporadic, which means that the emergence of clinical 
symptoms occur in the seventh decade of life. However, less than 1% of AD 
cases show clinical symptoms at an early age and are inherited in an 
autosomal-dominant mendelian fashion (Van Gassen and Van Broeckhoven, 
2000). These are referred to as FAD. Despite the disparity in the age of onset, 
both forms share common histopathological features: the extracellular deposition 
of neuritic and non-neuritic plaques that are composed of Aβ and intracellular 
NFT. 
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Three genes have been identified associated with early onset of familial 
Alzheimer’s disease (EOFAD): the PS1, PS2 and APP genes located at 
chromosomes 14, 1, and 21 respectively (Hardy and Higgins, 1992; Hardy, 1997). 
 
2.3.1 The Presenilin  
Mammalian PS1 and PS2 are evolutionary conserved integral membrane 
proteins with a molecular weight of 50 kDa, each is predicted to traverse the 
membrane 6-10 times. The amino and carboxyl termini are both oriented towards 
the cytoplasm (Hutton and Hardy, 1997). Endoproteolytic cleavage generates 
two fragments that remain associated. The presenilin holoproteins and their 
endoproteolytically cleaved fragments are components of high molecular weight 
protein complexes that reside in the ER and the Golgi apparatus (Annaert et al., 
1999). The amino acid sequence identity between PS1 and PS2 is approximately 
60% as a whole and about 90% within the transmembrane domain. Human PS1 
and PS2 express distinctly in human tissue. PS1 is transcribed uniformly 
throughout the brain and peripheral tissue. On the other hand, PS2 is transcribed 
at relatively low levels in the brain, except for the high levels in corpus callosum. 
It is highly expressed in some peripheral tissue, such as pancreas, heart, and 
skeletal muscle (Rogaev et al., 1997). It has been well established that 
presenilins are required for the γ-secretase cleavage of APP to generate Aβ and 
AICD and also for the S3 cleavage of Notch family receptors generating notch 
intracellular domain (NICD) (Kopan and Goate, 2000). Presenilins are important 
components of γ-secretase assembly along with other components: Nicastrin, 
aph-1 and Pen-2 (see below).  
In contrast to mutations in the PS1 gene, mutations in the PS2 gene are rare 
causes of FAD. Approximately 50% of EOFAD cases are associated with 
mutation in the PS1 gene (Tandon et al., 2000). To date, at least 73 different 
pathological mutations have been reported in the PS1 gene, some of which are 
shown in fig 2.2 (Tandon and Fraser, 2002). The majority are missense 
mutations. Mutations in presenilins cause increased generation of Aβ42. Two of 
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the important mutations identified are of two highly conserved aspartate residues 
in the transmembrane domains 6 and 7 of PS1 (Asp257 and Asp385). These 
mutations inhibit the biological function of presenilin required for  γ-secretase 
activity (Wolfe et al., 1999). It has been shown that PS1 D385N mutation acts like 
a dominant negative mutation (Steiner et al., 1999b). Both aspartate residues at 
257 and 385 are supposed to form the catalytic centre of the γ-secretase 
complex (Edbauer et al., 2003; Iwatsubo, 2004). PS1 with A257 and A385 
mutations integrate poorly into the heteromeric complex of γ-secretase, raising 
the possibility that these transmembrane domain mutations disable PS1 
structurally (Yu et al., 2000a). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 2.2: Schematic representation of PS1 showing eight transmembrane domains (TM). The 
boxes indicate some of the mutations identified in various regions of PS1. Mutations of two highly 
conserved aspartate residues (shown in red) in the transmembrane domain 6 and 7 inactivate 
γ-secretase activity and reduce Aβ and AICD generation (Diagram is compiled from the 
information in Steiner and Haass, 2000 and Tandon and Fraser, 2002) 
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2.3.2 The Amyloid Precursor Protein  
2.3.2.1 Amyloid Precursor Protein gene 
The human APP gene is 400 kb located in the mid portion of the long arm of 
chromosome 21 (Tanzi et al., 1987; Goldgaber et al., 1987). The amino acid (AA) 
sequence deduced from the APP cDNA predicted a large precursor of 695 AA, 
with a single hydrophobic stretch near its carboxyl terminal, containing properties 
of a membrane spanning domain, a 17 residue signal peptide for transport into 
ER and two consensus sequences for N-glycosylation in the large ectodomain 
(Kang et al., 1987). The APP gene consist of 18 exons and is alternatively 
spliced to generate at least 10 different APP variants (Octave, 1995). The three 
major spliced variants are APP770 when all exons are present, while APP751 
lacks exon 8 and APP695 lacks exon 7 and 8. 
 
2.3.2.2 Amyloid Precursor Protein expression  
From the early stages of embryonic development, APP mRNA is detectable in 
most tissues (Fisher et al., 1991; Lorent et al., 1995). APP is widely expressed 
throughout the body with particularly high expression in brain and kidney. 
Expression of APP in a variety of cell types, ranging from neurons to glial cells, 
platelets, endothelial cells, epithelial cells and fibroblasts, suggest an important 
role for APP in fundamental cellular processes (Arai et al., 1991; Forloni et al., 
1992; Mattson, 1997),  
APP is evolutionarly conserved and detected in a variety of mammals. 
Homologous proteins have also been identified in lower organisms, including 
Saccharomyces cerevisae, Caenorhabditis elegans and Drosophila 
melanogaster (Rosen et al., 1989; Daigle and Li, 1993; Zhang et al., 1994)  . Two 
mammalian proteins that are highly homologous to APP are Amyloid precursor 
like protein 1 and 2 (APLP1 and APLP2). The discovery of APLPs classifies APP 
as a member of a multigene family (Wasco et al., 1992; Slunt et al., 1994). APP, 
APLP1 and APLP2 have the structure of type I integral membrane glycoproteins 
with a major extracellular component and a short cytoplasmic tail. All the three 
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proteins are processed in a similar way leading to the secretion of large 
ectodomains. The expression of APLP2 overlaps largely with that of APP, 
whereas APLP1 is primarily expressed in the nervous system. The APLPs do not 
contain Aβ-like sequence (Wasco et al., 1993; Zhong et al., 1996), therefore do 
not seem to play a role in AD. 
 
2.3.2.3 Amyloid Precursor Protein processing 
APP is cotranslationally translocated into the ER by its signal peptide and 
matures through the central secretory pathway, with only a small percentage of 
holoproteins reaching the cell surface where it is acted upon by different 
secretases and is cleaved. About 23 AA hydrophobic stretch near its C-terminal 
region serves as an anchor in internal membranes (ER, Golgi, trans-Golgi 
network, endosome and in plasmalemma.)  
There are two major pathways through which APP can be processed and are 
known as either non-amyloidogenic pathway or  amyloidogenic pathway (Fig 2.3) 
(Selkoe, 1994; Octave, 1995; De Strooper and Annaert, 2000)). In the non-
amyloidogenic pathway, the principal cleavage is performed by a protease 
named α-secretase that cleaves within the Aβ sequence and precludes the 
formation of Aβ. In amyloidogenic pathway, cleavage involves β-secretase and 
eventually results in production of Aβ-peptide. 
 
 
 
 
 
 
 
 
 
 
                                                                                                              Introduction               
 - 14 -
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 2.3: Schematic representation of the proteolytic processing of APP. APP undergoes two 
endoproteolytic pathways that either preclude the formation of Aβ (Non-amyloidogenic pathway) 
or cause the formation of Aβ (Amyloidogenic pathway). In non-amyloidogenic pathway cleavage 
by α-secretase occurs within the Aβ domain (between residues 16 and 17 of Aβ sequence, 
shown in red). This results in the release of soluble N-terminus sAPPα and a membrane 
anchored C-terminus named as C83 fragment. α-secretase cleavage is followed by γ-secretase 
cleavage to liberate the P3 peptide. In amyloidogenic pathway, APP is first cleaved by β-
secretase at the N-terminus region of the Aβ sequence. This cleavage generates a slightly 
shorter soluble N-terminus sAPPβ fragment and a membrane anchored C-terminus fragment 
named as C99. Cleavage by β-secretase is followed by γ-secretase that occurs first at the 
recently elucidated ε-site within the transmembrane domain liberating 50 AA fragment known as 
APP intracellular domain (AICD) and then at the γ-secretase site after residue 40 or 42 of Aβ 
domain to liberate Aβ40 or Aβ42. 
 
 
Non-amyloidogenic pathway 
APP is synthesized as an integral membrane protein, and becomes N- and O- 
glycosylated, sulphated, phosphorylated and endoproteolytically processed 
during its transit from ER to the cell surface. In the non amyloidogenic pathway, 
APP is predominantly cleaved by α-secretase, between amino acid 16 and 17 of 
COOHNH2
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the amyloid region, precluding the formation of Aβ-peptide (Fig 2.3) (Anderson et 
al., 1991; Wang et al., 1991; Zhong et al., 1994). This cleavage results in the 
release of the large soluble fragment of APP (100-120 kDa), named as  sAPPα, 
and the generation of a truncated membrane anchored C-terminal fragment of 
about 10 kDa named as α-stub or C83 fragment (Weidemann et al., 1989; 
Schubert et al., 1989; Esch et al., 1990; Sisodia et al., 1990). α-secretase 
cleavage occurs intracellularly, predominantly after N- and O-glycosylation and 
sulphation, in a late compartment of the secretory pathway as well as at the 
plasma membrane. The 10 kDa C-terminal fragment is further processed to 
generate a secreted P3 peptide, by γ-secretase cleavage, which has been 
hypothesized to occur in early endosomes (Haass and Selkoe, 1993; Checler, 
1995; Selkoe, 1998). The biological significance of P3 and its role, in 
amyloidogenesis, if any, remains obscure. As cleavage of APP by α-secretase 
destroys the Aβ sequence, it is generally thought that the α-secretase pathway 
extenuate amyloid formation, although this has not been demonstrated clearly. In 
addition, the C-terminally truncated form of APP released by α-secretase may 
have trophic actions (Small, 1998) which could antagonize the neurotoxic effects 
of aggregated Aβ (Mok et al., 2000). Most recently two members of ADAM (a 
disintegrin and metalloprotease) family, tumor necrosis factor-α (TNF-α) 
converting enzyme (TACE or ADAM-17) and ADAM-10, are reported as most 
interesting  candidate for α-secretases (Buxbaum et al., 1998; Lammich et al., 
1999). 
 
Amyloidogenic pathway 
Since the first proteolytic processing event defined for APP was “normal” 
α-secretory cleavage within the Aβ region, it was assumed that “abnormal” or 
pathological processing must occur to generate the Aβ-peptide, necessitating an 
unusual cleavage in the transmembrane domain of APP. This concept was  
revivified when Aβ peptides were detected in the conditioned medium of many 
cultured cells and in the cerebrospinal fluid of cognitively normal individuals 
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(Seubert et al., 1992; Shoji et al., 1992; Haass et al., 1992b; Busciglio et al., 
1993). Subsequent extensive biochemical analysis demonstrated that Aβ is 
generated by endoproteolytic cleavage of APP by β-secretase followed by γ-
secretase (Fig 2.3) (Haass and Selkoe, 1993). β-secretase cleavage of APP 
releases a truncated soluble ectodomain of APP, named sAPPβ (Seubert et al., 
1993) and generates a membrane retained amyloidogenic C-terminal fragment of 
about 12 kDa, named as β-stubs or C99 fragments. C99 fragments are further 
processed by γ-secretase to generate Aβ peptides of varying lengths i.e. between 
40 and 42 AA and a residual C-terminal fragment of  nearly 7 kDa, named as 
AICD (APP intracellular domain) (Fig 2.3).  
The subcellular compartment of Aβ generation is still not clearly identified. 
However, an approximate localization can be established by defining where one 
can detect their respective cleavage products i.e. sAPPβ, C99 and the amyloid 
peptides Aβ40 and Aβ42. Generation of Aβ-peptides was observed to be 
dependent on re-internalization of cell surface APP that escapes α-secretase 
cleavage. This was evidenced most clearly by the detection of radio-iodinated Aβ, 
following reinternalization of radio-iodinated cell surface APP (Koo and Squazzo, 
1994). The internalization of APP is believed to employ the cytoplasmic domain 
of APP which contains a YENPTY signal mediating endocytosis of APP. The 
cells lacking this domain of APP show decreased Aβ formation (Golde et al., 
1992; Haass et al., 1993; Lai et al., 1995). Moreover, agents interfering with the 
acidification of subcellular compartments, i.e. ammonium chloride and 
chloroquine, inhibit the production of Aβ (Shoji et al., 1992; Haass et al., 1993). 
This implies that Aβ is generated in an acidic compartment following endocytosis, 
which could be congruent with early endosomes. Since, Aβ formation was not 
completely abolished by inhibition of reinternalization of APP, an additional 
pathway independent of APP reinternalization might exist.  
Using a variety of control experiments including brefeldin A and temperature 
blocks, pulse chases, immunocytochemistry and addition of an ER retrieval 
signal to APP, it was surprisingly found that Aβ42 is produced in high amounts in 
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neuronal ER  while the trans-Golgi network (TGN) was found to be the site for 
Aβ40 generation (Hartmann et al., 1997; Cook et al., 1997).  
In contrast to α- and γ-secretases, β-secretase appears to be a sequence 
specific endoprotease (Citron et al., 1995). Radio sequencing demonstrates that 
Aβ isolated from amyloid plaques and cell lines, predominantly begins at the Asp 
+1 residue of Aβ (Gouras et al., 1998; Cai et al., 2001). Interestingly, a mutation 
in APP called Swedish mutation (so called because it was discovered in a 
Swedish family) is located near the β-secretase cleavage site causes FAD. This 
mutation is double mutation which involves amino acid substitution of Lys-
Met?AsnLeu and is located immediately N-terminal to the β-secretase cleavage 
start site (Asp) of APP (Fig 2.4). The expression of this mutant causes APP to be 
a much better substrate for β-secretase and dramatically increases secretion of 
Aβ starting at Asp+1 (Citron et al., 1992; Cai et al., 1993) .  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 2.4: The sequence of APP containing the Aβ domain (shown in red) and transmembrane 
region is expanded and shown as single letter amino acid code. The shaded vertical box 
indicates the Swedish double mutation which is located immediately N-terminus to the β-
secretase cleavage start site. The normal cleavage site of β, α, γ, ε-secretases are indicated by 
arrows. 
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β-secretase activity in cells efficiently cleaves only membrane bound APP. On 
the other hand, transfection of APP constructs lacking the transmembrane 
domain are not cleaved by β-secretase (Citron et al., 1992). This implies that 
β-secretase is likely to be a membrane bound protease or, alternatively, it could 
be tightly associated with a membrane protein. β-secretase shows maximal 
activity at acidic pH, since agents that disrupt intracellular pH also inhibit 
β-secretase activity (Haass et al., 1993; Knops et al., 1995; Haass et al., 1995a). 
Moreover, β-secretase activity is highest in the acidic subcellular compartments 
of the secretory pathway, including the golgi apparatus and endosomes (Koo and 
Squazzo, 1994; Haass et al., 1995b). These data suggest that the active site of 
β-secretase is located within the lumen of acidic intracellular compartments. 
Recently, a most interesting candidate for β-secretase called β-site APP cleaving 
enzyme 1 (BACE1, also called Asp2 and memapsin2), a novel transmembrane 
aspartic protease has been identified by four independent groups. BACE 1 
exhibits all the properties of β-secretase and as a key enzyme that initiates the 
formation of Aβ (Hussain et al., 1999; Sinha et al., 1999; Vassar et al., 1999; Yan 
et al., 1999). 
Cleavage by γ-secretase takes place at multiple sites in C99 fragments, 
generating Aβ molecule that ends at amino acids 38, 39, 40, 42 or 43 of the Aβ 
domain. However the most abundant species found in vivo are Aβ40 and Aβ42. 
Among these Aβ42 is the most amyloidogenic form. Cell based systems that 
have been used to characterize γ-secretase generate 80-90% Aβ40 and 10-20% 
Aβ42, consistent with the ratio found in plasma and cerebrospinal fluid of humans 
(Mehta et al., 2001; Ertekin-Taner et al., 2001). Mutations in APP, PS1 and PS2 
genes that cause EOFAD result in a selective increase in Aβ42 production (Esler 
and Wolfe, 2001). Since γ-secretase mediated cleavage of APP defines the 
C-terminus of Aβ, it is likely that activity of this enzyme contributes substantially 
to the rate of developing sporadic as well as familial AD. γ-secretase shows 
unusual properties of cleavage within the lipid bilayer where it hydrolyses the β-
secretase generated membrane tethered C-terminal fragment of APP (named 
C99) in a water excluded environment. Several lines of evidence suggest that 
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presenilins are closely related to γ-secretase activity. The first evidence is given 
by the fact that FAD linked mutations of presenilins shifted the preferred site of 
γ-cleavage from position 40 to 42 of Aβ. Secondly, γ-secretase activity is 
diminished in cells derived from PS1 knockout mouse (De Strooper et al., 1998). 
Thirdly, substitution of either of the two aspartate residues in the 6 and 7 
transmembrane domains of PS1  (D257 and D385) abolished γ-secretase activity 
(Steiner et al., 1999a; Wolfe et al., 1999; Kimberly et al., 2000). Despite of the 
strong evidence, presenilin alone is not sufficient for the secretase activity as it’s 
overexpression does not increase the γ-secretase activity. Other cofactors that 
were identified for γ-secretase activity are nicastrin, Aph-1 and PEN-2   (Yu et al., 
2000b; Goutte et al., 2002; Francis et al., 2002). RNAi of each of the four 
fragments (PS, nicastrin, Aph-1 and PEN-2) in drosophila Schneider (S2) cells 
and in mammalian cells disrupts γ-secretase activity (Steiner et al., 2002; 
Edbauer et al., 2002b; Kimberly et al., 2003). Subsequently, it was also 
reconfirmed that expression of these four proteins in yeast, which lacks 
endogenous γ-secretase activity, reconstitute γ-secretase activity (Edbauer et al., 
2003). However, recent studies by two independent groups show that all 
components of γ-secretase are assembled in early compartments of the 
secretory pathway and that this complex is transported to late compartments in 
which substrates (e.g. APP or Nicastrin) are encountered and subsequently 
processed within respective transmembrane segments (Kim et al., 2004; Capell 
et al., 2005). 
 
2.4 Cellular Ca2+ homeostasis 
Calcium (Ca2+) is a ubiquitous intracellular signal responsible for controlling 
numerous cellular processes (Berridge, 1993; Berridge et al., 1998; Berridge et 
al., 2000). Cells at rest have a Ca2+ concentration of about 20-100 nM but when 
activated the Ca2+ concentration rises to roughly 10-200 µM. The Ca2+ 
concentration inside cells is regulated by the simultaneous interplay of multiple 
counteracting processes, which can be divided into “Ca2+ ON” and “Ca2+OFF” 
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mechanisms depending on whether they serve to increase or decrease cytosolic 
Ca2+  concentration (Berridge et al., 2000) (Fig 2.5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 2.5: Cells maintain Ca2+ signaling by regulating influx of Ca2+ into the cell from the 
extracellular medium (1.8 mM) or by its release from the intracellular stores. At rest cytosolic Ca2+ 
levels are maintained at levels ranging between 20 to 100 nM. The Ca2+ concentration in the 
lumen of ER ranges between 10-200 µM. Ca2+ release from ER occurs through either IP3 
receptors or ryanodine receptors. On the other hand cell regulates Ca2+ entry from the 
extracellular medium through different type of channels on the plasma membrane; Voltage gated 
calcium channels or Store operated calcium channels. Ca2+ efflux from the cytosol occurs through 
plasma membrane calcium ATPase in an ATP dependent manner. The cytosolic Ca2+ load is also 
replenished back into the ER by ATP dependent sarco-endoplasmic Calcium ATPase pump 
(SERCA). Mitochondria are also known to buffer cytosolic Ca2+ in low amounts aided by a 
uniporter. The Ca2+ efflux from mitochondria occurs through Na+/ Ca2+ exchanger. 
 
2.4.1 “Ca2+ ON” mechanisms 
The “Ca2+ ON“ mechanisms include channels that aid to increase cytosolic Ca2+. 
Some of these channels are located at the plasma membrane and regulate the 
supply of Ca2+ from the extracellular space where Ca2+ concentration is about 
1.8 mM. Other channels regulate the release of Ca2+ from intracellular stores into 
the cytosol, for instance channels on ER membrane. 
Store operated
calcium channels
Voltage gated
calcium channels
Plasm a m em brane
calcium ATPase pum p
SERCA 
pum p
Ca2+ Ca2+ Ca2+
Ca2+
Ca2+
Ca2+
Mitochondria
[Ca2+]i = 20-100 nM
[Ca2+]i = 1.8 m M
C ytosol
Plasm a 
m em brane
ATP
Ca2+
InsP3R RyR
Endoplasm ic
Reticulum
[Ca2+]i = 10-200 µM
Na+/Ca2+
exchanger
Uniporter
                                                                                                              Introduction               
 - 21 -
 Channels on the plasma membrane include Voltage operated calcium channels 
(VOCC), receptor-operated calcium channels (ROCCs) and store operated 
calcium channel (SOCCs) (Fig 2.5). VOCCs are largely expressed by excitable 
cell types such as neuronal and muscle cells, where they are activated by 
depolarization of the plasma membrane. ROCCs are activated by the binding of 
an agonist like glutamate, ATP or acetylcholine to the extracellular domain of the 
channel. SOCCs are activated in response to depletion of the intracellular Ca2+ 
store either by physiological Ca2+ mobilizing messengers or pharmacological 
agents. This mechanism is termed as “Capacitative Calcium Entry (CCE)” 
(Putney, Jr., 1986). CCE is a normal physiological phenomenon taking place 
predominantly in non-excitable cells. Recent reports have indicated that this 
phenomenon also plays an important physiological role in many, but not all 
excitable cells where it functions in the generation of cytoplasmic Ca2+ signals 
with cell specific functions (Antaramian et al., 2001). The mechanism by which 
the SOCCs sense the filling status of the intracellular pool is still unknown.  
Ca2+ release from the ER occurs through two types of Ca2+ channels: inositol-
1,4,5-triphosphate receptors (IP3Rs) and ryanodine receptors (RyRs) (Fig 2.5). 
Release through IP3Rs requires the activation of G protein on the cell surface 
that induce phospholipase C (PLC) to cleave phosphatidylinositol-4,5-
biphosphate (PiP2) into diacylglycerol and IP3. IP3 encounters with IP3Rs and 
causes the channels to open, thus allowing the Ca2+ stored at high concentration 
in the ER/SR to enter the cytoplasm. Ryanodine receptors are structurally and 
functionally analogous to IP3Rs and are activated by binding of ryanodine 
(Franzini-Armstrong and Protasi, 1997). As a result of these ON mechanism Ca2+ 
flows into the cytoplasm to produce the increase in concentration that constitutes 
a Ca2+ signal. 
 
2.4.2  “Ca2+OFF” mechanisms 
Once Ca2+  has carried out its signaling functions, it is rapidly removed from the 
cytoplasm by various pumps and exchangers (Pozzan et al., 1994; Blaustein and 
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Lederer, 1999). The plasma membrane Ca2+ATPase (PMCA) pump extrudes 
Ca2+ to the outside and sarco-endoplasmic Ca2+ATPase (SERCA) pump returns 
Ca2+ to the internal stores (Fig 2.5). The Ca2+ concentration in ER and in 
extracellular space is much higher than in cytosol, therefore the Ca2+ extrusion 
by these pumps work against a high concentration gradient and is ATP 
dependent. In addition to it, there are also Na+/Ca2+ exchangers that also extrude 
Ca2+ to the outside from the cytoplasm.  
The mitochondria is another important component of OFF mechanism in that it 
sequesters Ca2+  under conditions of local elevated cytoplasmic Ca2+  and then 
releases it back slowly during the recovery phase (Fig 2.5). The uptake of Ca2+ 
by mitochondria is, in fact, not mediated by pumps or exchangers, but by a 
“uniporter” possibly a gated channel (Nicholls and Crompton, 1980). The 
molecular identity and nature of the uniporter is unknown. The uniporter provides 
a pathway for the accumulation of the Ca2+ into the mitochondrial matrix, driven 
by the electrochemical potential gradient across the inner mitochondrial 
membrane, usually estimated at 200 mV negative to the cytosol, and generated 
either by respiratory chain or ATP hydrolysis. However, the uniporter has a very 
low affinity for Ca2+ and has been demonstrated that mitochondria sequester only 
very low amounts of Ca2+  (Somlyo et al., 1979). The Ca2+ efflux from 
mitochondria back into the cytosol is mediated by two types of exchangers 
namely, Na+/Ca2+ and H+/Ca2+ exchangers (Nicholls and Crompton, 1980; 
Carafoli, 2003).  
 
2.5 Alzheimer’s disease and Ca2+ dyshomeostasis 
Deregulation of intracellular Ca2+ signaling has been implicated in the 
pathogenesis of AD. The “Ca2+ hypothesis of Alzheimer’s disease“ was first 
proposed by Khachaturian (Khachaturian, 1989). Its basic tenet is that sustained 
disturbances in Ca2+ homeostasis are a proximal cause of neurodegeneration in 
Alzheimer’s disease. One parameter of Ca2+ homeostasis in normally aged 
neurons is the enhanced value of resting intracellular Ca2+ values. Significant 
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increase in resting cytosolic [Ca2+]i with aging has been reported in 
synaptosomes obtained from the aged brains and in acutely dissociated neurons 
isolated from hippocampus or neocortex (MartInez et al., 1988; Villalba et al., 
1995; Kirischuk and Verkhratsky, 1996). Similar increase has been reported for 
peripheral neurons and for cerebellar purkinje neurons recorded in brain slice 
(Kirischuk and Verkhratsky, 1996). The issue of the resting (or basal) intracellular 
Ca2+ values in the aged neurons is central for the “Ca2+ hypothesis” of neuronal 
aging. At steady state, the resting Ca2+ values represent the balance between the 
Ca2+ entry system (mainly Ca2+ permeable channels) and Ca2+ removal system 
(mainly Ca2+ pumps). Even a minimal dysfunction in any of these systems 
determine over a period of time a resetting of the steady state value of resting 
Ca2+ .  
Studies of the pathogenic mutations in PS1, PS2 and APP gene responsible for 
EOFAD have established central roles for perturbed cellular Ca2+ homeostasis. 
Ca2+ deregulation in AD includes APP processing regulation, ER dysfunction, 
mitochondrial changes and gene expression alterations. 
 
2.5.1 Presenilins and  Ca2+ dyshomeostasis 
Presenilins contribute to neurodegeneration in AD mainly through the modulation 
of Ca2+ signaling in the ER. A pathological role for mutant PS1 in modulating IP3 
evoked Ca2+  release from the ER is shown by several groups in a variety of 
systems, including Xenopus oocyte, neural and non-neural cell lines, primary 
neurons and transgenic mice. For example, studies in fibroblast harbouring 
A246Q mutation of PS1 shows as enhanced IP3 mediated Ca2+  liberation, 
therefore exhibiting an enhanced ER Ca2+  content, altered resting Ca2+  levels 
and altered mitochondrial functions (Peterson and Goldman, 1986; Gibson et al., 
1996; Hirashima et al., 1996; Leissring et al., 1999b). Clinical mutation in the PS2 
gene also enhances IP3 evoked Ca2+ release from the ER.  For instance, PS2 
harboring FAD mutation ( N141I , M239V)  in Xenopus oocyte is reported to 
exhibit enhanced IP3 mediated Ca2+ release (Leissring et al., 1999a). This finding 
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reveals that a pathological pathway involving the destabilization of Ca2+   
homeostasis is common to both PS1 and PS2. Studies in transgenic mice 
harboring M146L mutation in PS1 exhibits disruption of the control of intracellular 
Ca2+, abnormal synaptic Ca2+ homeostasis and mitochondrial dysfunction 
(Begley et al., 1999; Barrow et al., 2000).  Abrogation of functional PS1, by either 
knocking out PS1 or expressing inactive PS1 reduces ER Ca2+ storage (Yoo et 
al., 2000; Leissring et al., 2002) and potentiates Capacitative calcium entry 
(CCE) (Yoo et al., 2000). Likewise, the release of Ca2+ from ER stores after 
treatment with thapsigargin, an irreversible inhibitor of the SERCA pump, was 
also elevated in cells that expressed physiological levels of mutant PS1 
(Leissring et al., 2000). Over expression of the PS1 ΔE9 (exon 9 deleted PS1) 
mutation in neuroblastoma cells also increases Ca2+  stores (Smith et al., 2002). 
Conversely, Ca2+  stores are diminished in presenilin-deficient cells (Leissring et 
al., 2002). All these evidences show that presenilins play a very critical role in 
regulating Ca2+ homeostasis in the ER.  
 
2.5.2 Amyloid Precursor Protein and Ca2+ dyshomeostasis  
There have been considerable reports that link altered processing of APP to 
disruption of neuronal Ca2+ homeostasis and an excitotoxic mechanism of cell 
death in AD. Generally, secreted N-terminal molecules of APP (sAPPα or 
sAPPβ) normalize cytosolic Ca2+ levels and are regarded as neuroprotective 
(Goodman and Mattson, 1994). sAPPα or sAPPβ has been shown to moderate 
Ca2+ responses in hippocampal neurons after exposure to glutamate, and can 
protect neurons against excitotoxicity (Mattson et al., 1993a; Mattson, 1994; 
Koizumi et al., 1998). These molecules have also been shown to protect the cells 
against the pro-apoptotic effects of mutant PS1, and this effect is mediated by 
the stabilization of intracellular Ca2+ (Guo et al., 1998b).   
Whereas sAPPα or sAPPβ is supposed to be neuroprotective and normalizes 
cytosolic Ca2+ levels, a series of studies yielded conflicting data concerning the 
possible neurotoxicity of Aβ. However, quite a number of reports have shown that, 
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in fact, Aβ may or may not be neurotoxic depending upon whether or not it is in 
an aggregated state. For instance, it was shown that fresh unaggregated Aβ was 
not neurotoxic but if left for 2-4 days incubation prior to addition to the cultures 
resulted in aggregation and neurotoxicity (Pike et al., 1991). Subsequently, a 
direct relationship between peptide aggregation and neurotoxic potency was 
shown (Pike et al., 1991; Busciglio et al., 1993; Mattson et al., 1993b). These 
experimental studies are consistent with the observed AD pathology in which 
only plaques containing aggregated Aβ are associated with neuronal 
degeneration. The mechanism of Aβ toxicity was examined in a series of studies 
on cultured human cortical and rat hippocampal neurons. Chronic exposure of Aβ 
results in an elevation of resting Ca2+ values and increased Ca2+  responses to 
depolarization (Mattson et al., 1992; Mattson et al., 1993b).  
As described in the preceding text, APP undergoes presenilin dependent 
γ-secretase cleavage generates Aβ peptides and AICD. Recently it has been 
shown that AICD regulates phosphoinositide mediated Ca2+  signaling through a 
γ-secretase dependent signaling pathway (Leissring et al., 2002). A recent report 
shows that elevated β-secretase (BACE1) expression in sporadic AD may induce 
the increase in β-CTF (sAPPβ) and Aβ but cause a reduction of AICD generation 
(Kume et al., 2004). This infers that as AICD has been shown to play a role in 
signal transduction, a decreased levels in sporadic AD brain may induce signal 
transduction failure (Cao and Sudhof, 2001; Scheinfeld et al., 2003), Interestingly, 
it has been reported that some PS1 mutations causing EOFAD, inhibit the 
generation of AICD (Chen et al., 2002). Therefore, AICD may be a key molecule 
for the elucidation of AD pathology.  
A large body of work shows that Ca2+ signaling can be disrupted by derivatives of 
APP but until now no definitive role for different cleavage products of APP 
playing role in Ca2+ homeostasis, has been ascribed.  
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2.5.3 Mitochondrial dysfunction and Ca2+ homeostasis 
Mitochondria play a complex multifactorial role in the cell. In addition to their 
primary role in ATP generation, the organelles also sequester Ca2+  (Gunter et al., 
1994) . These functions are intimately interlinked through the central bioenergetic 
parameter of the proton electrochemical gradient across the inner mitochondrial 
membrane which is generated as a result of oxidative phosphorylation. The 
NADH and FADH2 formed in glycolysis, fatty acid oxidation and the citric acid 
cycle are energy rich molecules because each contains a pair of electrons having 
a high transfer potential. The flow of electrons from NADH or FADH2 to O2 
through protein complexes (named as complex I-IV) located in the mitochondrial 
inner membrane leads to the pumping of protons out of the mitochondrial matrix 
(Fig 2.6). The resulting uneven distribution of protons generates a pH gradient 
and a transmembrane electrical potential (Δψm), both of these components 
together constitutes a proton motive force (∆p). ATP is synthesized when proton 
flow back to the mitochondrial matrix through an enzyme complex named as ATP 
synthase (Fig 2.6). The proton motive force generated through this process is 
about 200 mV. Under most conditions Δψm is the dominant component of ∆p 
which normally accounts for about 80% of ∆p (Mitchell and Moyle, 1969; Nicholls, 
1974). Therefore, mitochondrial membrane potential is usually used for a 
measure of mitochondrial activity and relative ATP production. Because the 
proton circuit is completed by the reentry of protons through the ATP synthase, 
which in turn is tightly coupled to ATP synthesis, it follows that the proton current 
responds automatically to the ATP demand. Tight coupling between electron flux 
and proton pumping in each respiratory chain complex means that electron flux 
(and hence respiration) is in turn controlled by ATP demand.  
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Fig 2.6: NADH and FADH2 are high energy electron carriers generated through citric acid cycle. 
Electrons from NADH and FADH2 enters the electron transport chain at respectively complex I 
and complex II. The flow of electrons from complex  I to IV  leads to pumping of protons out of the 
mitochondrial matrix. Complex I, III and IV function as proton pumps. The resulting uneven 
distribution of protons generates a pH gradient and a transmembrane electrical potential that 
creates a proton motive force. ATP is synthesized when protons flow back to the mitochondrial 
matrix through an enzyme complex called ATP synthase that catalyses the synthesis of ATP. Due 
to this phenomenon, the mitochondrial membrane potential is negative on the matrix side and 
positive on the cytosolic side. 
 
 
The mitochondrial membrane potential Δψm, not only serves as a key 
intermediate in the synthesis of ATP but can also be utilized to accumulate Ca2+ 
(Gunter and Gunter, 1994). Uptake of Ca2+ by mitochondria is mediated by a 
uniporter which is activated by elevated cytoplasmic Ca2+ and which allows Ca2+ 
to enter the matrix down the steep electrochemical gradient (composed mostly of 
a – 150 to – 180 mV mitochondrial membrane potential, ψm) that is maintained by 
selective pumps and conductances. Mitochondrial Ca2+ uptake increases the 
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activity of several dehydrogenases (McCormack et al., 1990), which drives the 
operation of the electron transport chain and ATP synthesis, thereby matching 
energy production with demand (Duchen, 1999). Mitochondrial Ca2+ buffering is 
central to normal physiology and Ca2+ signaling. Therefore any alteration in any 
of these mitochondrial functions might be the underlying cause of disturbed Ca2+ 
homeostasis and altered energy metabolism, a characteristic of age related 
diseases like AD. 
Subtle changes in respiratory chain capacity, substrate supply, cytoplasmic Ca2+  
and membrane potential occur in aging. It has been shown that sustained 
elevation of cytoplasmic Ca2+ levels can promote mitochondrial oxyradical 
(superoxide) production, membrane depolarization and ATP depletion suggesting 
a contribution of altered Ca2+ homeostasis to mitochondrial dysfunction in AD 
(Guo et al., 1998a; Guo et al., 1999a). Conversely, impairment of mitochondrial 
function can result in increased cytoplasmic Ca2+ levels. Two independent 
reports on PC12 cells show that a rapid elevation of intracellular Ca2+, was 
followed by caspase activation, accumulation of reactive oxygen species (ROS), 
and decrease in transmembrane potential (Kruman et al., 1998; Keller et al., 
1998) . The Ca2+ chelator BAPTA-AM and agents that block Ca2+  release from 
ER and influx through voltage-dependent channels prevented mitochondrial ROS 
accumulation and membrane depolarization and apoptosis (Keller et al., 1998). 
Moreover, it was shown in rat cortical synaptosomes that ryanodine receptors 
were involved in ER-mediated  mitochondrial Ca2+ changes in AD (Mungarro-
Menchaca et al., 2002). Recent studies have suggested that Aβ may be directly 
toxic to mitochondria (Casley et al., 2002) and it also causes loss of cytochrome 
c oxidase activity in neurons in culture (Kim et al., 2002). The activities of key 
enzymes of glycolysis and the tricarboxylic acid cycle, pyruvate dehydrogenase 
complex and α-ketoglutarate dehydrogenase complex, was also found to be 
lower in brain taken post mortem from Alzheimer’s patients compared with 
control (Sorbi et al., 1983; Butterworth and Besnard, 1990; Mastrogiacomo et al., 
1993).  
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Taken together, the evidences described in the above sections strongly suggest 
that Ca2+ regulation employ PS1, PS2 and cleavage products of APP. The study 
of Ca2+ homeostasis therefore is the subject of key importance in aging and AD 
research and its fragmented knowledge attained until now deserves further 
consideration. 
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3 Aim of the study 
Alzheimer’s disease has a very complex and multifactorial etiology. The 
pathogenesis of AD is still not well understood and especially the precise cellular 
and molecular mechanisms that underlie the cause of disease. Lines of studies 
done on the pathogenic mutations in PS1, PS2 and APP in different cellular 
model have established central roles for disturbed Ca2+ homeostasis. But up to 
date no definitive mechanism have been described that underlie disturbances in 
Ca2+ homeostasis due to these mutations. The study done in this thesis is 
focused on the normal physiological role of APP and its cleavage products with 
regard to cellular Ca2+ homeostasis. The function of APP is unknown and 
ablation of APP gene does not lead to any substantial phenotype in gene 
targeted mice (Zheng et al., 1996). APP is a member of a gene family that 
includes Amyloid precursor like proteins APLP1 and APLP2, which might 
compensate for the loss of APP (Heber et al., 2000).  In a previous study, it was 
revealed that ablation of all the three family members leads to early postnatal 
lethality (Herms et al., 2004), indicating the importance of these proteins in the 
cell. 
Therefore the specific aims of the thesis are: 
 
A. To understand the role of APP and its cleavage products in maintenance 
of Ca2+ homeostasis.  
B. To study which cleavage product of APP processing is involved in ER 
Ca2+ storage and hence maintenance of Ca2+ homeostasis. 
C. To study the underlying mechanism that control Ca2+ homeostasis via 
APP or its cleavage products. 
D. To understand the disturbances in mechanisms caused as a result of 
altered APP processing. 
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4 Materials  
4.1 Cell lines 
4.1.1 Human embryonic kidney cells (HEK293 cells)  
HEK293 cells were courteously provided by Prof.Christian Haass (Adolf 
Butenandt Institute, Munich). The following stable cells lines of HEK293 cells 
were used : 
• Express human APP (wtAPP) (Haass et al., 1992a) 
• Express APP with swedish mutation (APPsw) (Citron et al., 1992) 
• Coexpress APPsw and PS1 with D385N mutation (PSD385N) (Capell et 
al., 2000) 
• Coexpress APPsw and insulin degrading enzyme (IDE) (Edbauer et al., 
2002a) 
 
4.1.2 Human neuroglioma cells (H4 cells) 
H4 cells were courteously provided by Ellen Kilger (Hertie Institut für Klinische 
Hirnforschung, Tübingen). The following stable cell lines under the control of 
“Tet-Off system” in H4 cells were used (Gossen and Bujard, 1992) : 
• Express inducible allele of AICD fragment with VSV tag (H4-AICD-VSV) 
• Express only regulator plasmid (H4-control) 
 
4.1.3 Primary culture of mouse astrocytes 
• App knockout mouse (App0/0) (Muller et al., 1994) 
• C57xSv129 mouse (Wt) 
 
4.2 Bacterial strain 
• E.coli DH5α (Hanahan, 1983) 
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4.3 Plasmids 
• pEGFP-N1 was purchased from clontech. 
• pcDNA3 (Invitrogen) encoding nucleotide sequence of AICD 
(pcDNA3-AICD). This construct was provided by Prof.Christian Haass. 
The AICD sequence was cloned between HindIII and XbaI restriction 
enzyme site in multiple cloning region.  
 
4.4 Microscopes 
• BX50WI upright microscope from Olympus (Germany) was used for 
imaging experiment. The 20X water immersion objective (UM plan FI) was 
also purchased from Olympus. 
• Axiovert 40CFL from Zeiss (Germany) was used for normal visualization 
of cells. 
 
4.5 Filter sets 
• Fura-2 filter set  (Till photonics, Germany) 
   Exciter filter   None 
   Dichroic mirror  DCLP410 
   Emission   LP470 
Where, DC and LP are abbreviations used by the manufacturer for dichroic 
and long pass filters respectively. 
• Fura-2/Rhodamine filter set (AHF analysen technik, Germany) 
   Exciter filter   None 
   Dichroic mirror  Dual band pass 
   Emission filter  Dual band pass 
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4.6 Antibodies 
• Anti-VSV mouse antibody was purchased from Sigma, Germany. 
• Anti-GSK-3β and Anti-GSK-3β (pY216) phospho specific mouse antibody 
was purchased from BD transduction laboratories, Germany. 
• Anti-β-actin rabbit antibody was purchased from Santa Cruz 
Biotechnology INC., USA. 
• Anti-Tim44 was courteously provided by Andreas Reichert (Adolf-
Butenandt institut für physiologische chemie, Munich) 
• Alkaline phosphatase conjugated anti-immunoglobulin mouse/rabbit 
antibody was purchased from DakoCytomation, Denmark. 
 
4.7 Commercial kits 
• Ca2+ calibration buffer kit     Molecular probes, Germany. 
• Bioluminiscent somatic cell assay kit   Sigma, Germany. 
• DNeasy tissue kit       Qiagen, Germany. 
• Plasmid midi kit       Qiagen, Germany. 
• Effectene transfection kit     Qiagen, Germany. 
4.8 Buffers 
All buffers were prepared in deionized water. 
4.8.1 Buffers for Ca2+ imaging 
HBSS buffer 
• NaCl     145 mM 
• KCl     2.5 mM 
• MgCl2    1 mM  
• HEPES    20 mM 
• Glucose    10 mM 
• CaCl2    1.8 mM 
pH was set to 7.2 before use. 
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HBSS buffer (Ca2+ free) 
• NaCl     145 mM 
• KCl     2.5 mM 
• MgCl2    1 mM 
• HEPES    20 mM 
• Glucose    10 mM 
• EGTA    50 µM 
pH was set to 7.2 before use. 
 
Fura-2/AM and rhodamine-123 loading buffer 
• HBSS buffer 
• Pluronic acid   0.08% 
• BSA     1% w/v 
 
4.8.2 Buffers for crude mitochondrial extraction 
Resuspension buffer (RSB buffer) 
• Tris-HCl (pH 7.5)  10 mM 
• EDTA    5 mM 
• CaCl2    1.5 mM 
 
Mannitol-Saccharose buffer (MS buffer) 
• Tris-HCl (pH 7.5)  10 mM 
• EDTA    5 mM 
• Mannitol    420 mM 
• Saccharose   140 mM 
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4.8.3 Buffers for western blotting 
Lysis buffer 
• SDS     0.1% (w/v) 
• NP40     1% (v/v) 
• Deoxycholate   0.5% (w/v)   
• Tris (pH 8.0)   10 mM 
• NaCl     150 mM 
 
Tricine-SDS running buffer 
• Tris-base    100 mM 
• Tricine    100 mM 
• SDS     0.1% (w/v) 
pH was set to 7.3. 
 
I–block 
• PBS     1 tablet per 1000 ml 
• I-block powder  0.2% (w/v) 
• Tween-20    0.1% (v/v) 
Heated at 60oC for 1 hour. 
 
Blotting buffer 
• Tris-HCl (pH 7.4)  25 mM 
• Glycine    200 mM 
• SDS     0.1% 
• Methanol    20%  
 
Laemmli buffer 
• EDTA (pH 8.0)  25 mM 
• SDS     7.5% (w/v) 
• Glycerin    50% (v/v) 
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• Bromophenol blue  2.5% (w/v) 
• β-mercaptoethanol 7.5% (v/v) 
• Urea     4 M 
 
TBS-Tween buffer 
• Tris-HCl    50 mM 
• Tween-20    0.1% 
• NaCl     100 mM 
pH was set to 7.4. 
 
Alkaline phosphatase buffer 
• Tris (pH 9.5)   100 mM 
• NaCl     100 mM 
• MgCl2    5 mM 
 
4.8.4 Buffer for agarose gel electrophoresis 
TAE buffer 
• Tris-HCl (pH 8.2)    40 mM 
• Acetic acid     20 mM 
• EDTA (pH 7.6)    2 mM 
 
4.8.5 Growth medium for bacterial cultures 
Lurea-bertani medium (LB medium) 
• Trypton    1% 
• Yeast extract   0.5% 
• NaCl     1% 
pH was set to 7.2. 
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Lurea-bertani agar plates 
• Lurea broth medium 
• Agar     1.5% 
 
4.9 Equipments 
• Centrifuge       5415 R, 5804 R, 5810 R 
           Eppendorf, Germany. 
• Microplate reader (Luminometer) BMG Labtech, Germany. 
• Gene pulser II (Electroporator)  Biorad, Germany. 
• Electroporation tubes (0.4 cm)  Gene pulser cuvette, Biorad, Germany. 
• Biophotometer     Eppendorf, Germany. 
• Vertical electrophoresis system  Invitrogen, Germany. 
• Horizontal electrophoresis system Peqlab, Germany. 
• Blotting apparatus     Hoefer semiphor, Amersham    
         pharmacia biotech., Germany. 
• pH meter       Heidolph instruments, Germany. 
• Incubators      Kendro, Germany. 
• PCR cycler      Eppendorf, Germany. 
• UV transilluminator    Vilber Lourmat, France. 
• Thermomixer      Eppendorf, Germany. 
• Water bath      GFL, England. 
• Pipetteman      Eppendorf, Germany. 
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4.10 Chemicals 
Table 1: List of chemicals 
 
No.         Chemical     Company 
1. 10-20% tricine-SDS gels Invitrogen, Germany 
2. Agar Becton Dickinson, Germany 
3. Agarose Peqlab, Germany 
4. Ampicillin Roth, Germany 
5. BCIP Roche, Germany 
6. Bovine serum albumin Sigma, Germany 
7. Cyclopiazonic acid Calbiochem, Germany 
8. Dimethyl malate Sigma, Germany 
9. Dimethyl succinate Sigma, Germany 
10. DMEM PAN, Germany 
11. DPBS PAN, Germany 
12. DTT Roche, Germany 
13. Ethidium bromide Sigma, Germany 
14. FCCP Sigma, Germany 
15. FBS PAA, Germany 
16. Fungizone Gibco, Germany 
17. Fura-2/AM Molecular probes, Germany 
18. G418 Sigma, Germany 
19. Gel loading solution Sigma, Germany 
20. Gentamicin Invitrogen, Germany 
21. Glutamax Invitrogen, Germany 
22. Glycine Sigma, Germany 
23. HBSS Invitrogen, Germany 
24. HEPES Sigma, Germany 
25. I-block Tropix, Germany 
26. Methyl pyruvate Sigma, Germany 
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27. MITO BD biosciences, Germany 
28. N2 supplement Invitrogen, Germany 
29. NBT Roche, Germany 
30. Oligomycin Sigma, Germany 
31. PBS tablets VWR, Germany 
32. Penicillin-streptomycin Invitrogen, Germany 
33. Pluronic acid Sigma, Germany 
34. Poly-d-lysine Serva, Germany 
35. Rhodamine-123 Molecular probes, Germany 
36. See blue protein marker Invitrogen, Germany 
37. SOC-medium Peqlab, Germany 
38. Sodium dodecyl sulphate Sigma, Germany 
39. Sodium-L-ascorbate Sigma, Germany 
40. TMPD Sigma, Germany 
41. Trypsin-EDTA Invitrogen, Germany 
42. Trypton Becton Dickinson, Germany 
43. Yeast extract Becton Dickinson, Germany 
44. Zeocin Invitrogen, Germany 
45. γ-IV Calbiochem, Germany 
 
Other general chemicals which are not mentioned in the table above were 
purchased from: 
• Merck, Germany 
• Sigma, Germany 
4.11 Other materials 
Plastic and related articles were purchased from: 
• Nunc, Germany 
• VWR, Germany 
• Peqlab, Germany 
• Abimed, Germany 
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4.12 Softwares 
• Till vision 4.0 (Till photonics, Germany) was used for Ca2+ imaging. 
• Fluostar optima (BMG Labtech, Germany) was used for luminescence. 
• Sigma plot 7.0 (Systat software Inc., USA) was used for calculating area 
under the curve. 
• Sigma stat 2.03 (Systat software Inc., USA) was used for statistical 
analysis. 
• Reference manager 10 (ISI Research soft., USA) was used for generating 
the literature list. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                 Methods               
 - 41 -
5 Methods 
5.1 Cell culture 
HEK293 cell lines were cultured in DMEM supplemented with 10% foetal bovine 
serum (FBS), 1% penicillin/streptomycin (pen./strep.) and 1% Glutamax at 37oC 
in 10% CO2 atmosphere.  
APPsw cells were cultured in DMEM supplemented with the selection antibiotic, 
G418 (0.2 mg/ml).  
wtAPP cells were cultured in DMEM supplemented with the selection antibiotic, 
G418 (0.2 mg/ml). 
APPsw/PSD385N cells were cultured in DMEM supplemented with the selection 
antibiotic G418 (0.2 mg/ml) and zeocin (0.2 mg/ml). 
APPsw/IDE cells were cultured in DMEM supplemented with the selection 
antibiotic G418 (0.2 mg/ml) and zeocin (0.2 mg/ml). 
H4 cells were cultured in DMEM supplemented with 10% FBS and 1% pen./strep. 
These cells express an inducible allele of AICD fragment with a C-terminal 
VSV-tag under the control of the “Tet-Off” system. The expression of AICD-VSV 
was turned off using doxycycline (100 ng/ml) in the growth medium. 
5.2 Preparation of primary culture of mouse astrocytes 
Primary cultures of astrocytes were prepared from homozygous App knockout 
mice (App0/0) on a C57xSv129 background (Muller et al., 1994). C57xSv129 wild 
type mice were used as a control. Astrocytes were prepared from cortical 
hemisphere of new born (1-2 days old) mice. The brain was dissected out in 
HBSS medium supplemented with 0.25 µg/ml of fungizone, 50 µg/ml of 
gentamicin and 1% pen/strep. The meninges and both the hippocampi were 
removed. The cortical hemispheres were separated out and transferred into the 
mixture of HBSS and 20% trypsin for 5 min. Subsequently, prewarmed DMEM 
was added and centrifuged at 200 x g. The pellet was resuspended in DMEM 
and transferred to the culture flask. The cultures were maintained in DMEM 
supplemented with 5% FCS, 1% pen./strep., 1% N2 supplement and 0.2% MITO 
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at 37oC for nearly one week. After about 1 week, when astrocytes have reached 
90-95% confluency, the flask was placed overnight on a laboratory shaker at 
fairly high agitation (agitation causes many of the process bearing cells like 
neurons to be shaken away) at 37oC. The medium was exchanged with fresh 
DMEM.  
5.3 Freezing of mammalian cells 
Cells were grown to 90-95% confluency in 100 mm petridishes, washed with 
warm PBS and trypsinized. Trypsinized cells were collected in falcon tubes and 
pelleted down at 700 x g for 5 min. The pellet was resuspended in FBS with 
10% DMSO to a final volume of 1 ml per plate. Aliquots were transferred to 
cryovials and were stored in freezing containers at -70oC. The cryovials were 
later transferred to liquid nitrogen for long term storage. 
5.4 Thawing of mammalian cells 
Frozen cryovials were transferred in water bath at 37oC for rapid thawing. The 
contents of the cryovials were transferred to 10 ml growth medium and 
centrifuged at 100 x g for 3 min. The media was removed and the pellet was 
washed similarly two times to remove DMSO. Finally, the pellet was 
resuspended in suitable growth medium, transferred to culture flasks and grown 
under requisite culture conditions. 
5.5 DNA isolation from rodent tails 
Tail of about 6 mm was cut from the mouse into a microcentrifuge tube. DNA 
isolation was done using DNeasy tissue kit according to the manufacturer’s 
protocol. Briefly, this procedure involves steps in which samples were lysed using 
proteinaseK and the lysate was loaded onto a DNeasy spin column. During 
centrifugation, DNA was selectively bound to the DNeasy membrane and 
contaminants were washed through. The DNA was eluted in TE buffer later on. 
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5.6 Genotyping  
App0/0 mice were genotyped routinely using DNA extracted from tail biopsies. The 
primers used are mentioned below: 
Primers: 
 
 
 
 
 
 
 
App0/0 1 and App0/0 2 primers were used for analyzing wild type allele and  
App0/0 2 and App0/0 3 primers were used for amplifying knockout allele using the 
following PCR conditions.  
For a 50 µl reaction volume, the following components were pipetted into a PCR 
tube: 
Reaction mixture: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For 1 sample
Mastermix (purchased
from Eppendorf) 25 µl
Primer 1 (25 pmol) 0.5 µl
Primer 2 (25 pmol) 0.5 µl
Water 22 µl
DNA 2  µl
App0/0 1
App0/0 2
App0/0 3
SequencePrimer
5‘ CGA GAT CAG CCT CTG TTC CAC A 3‘
5‘ ATC ACC TGG TTC TAA TCA GAG GCC C 3‘
5‘ GAG ACG AGG ACG CTC AGT CCT AGG G 3‘
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PCR programme: 
 
 
 
 
 
 
The PCR product was analyzed using agarose gel electrophoresis.  
 
5.7 Agarose gel electrophoresis 
The agarose gel was prepared by dissolving an appropriate amount of agarose 
(usually 1% final concentration) in 1X TAE buffer and ethidium bromide (1 µg/ml). 
The mixture was cooked and poured into precast agarose gel chambers. The 
DNA was mixed with the loading buffer (1:5) and loaded into spurs on the gel. 
The DNA was separated electrophoretically at 100 volts using 1X TAE as a 
running buffer. Finally, the DNA was visualized on a UV transilluminator. 
 
5.8 Ca2+ Imaging 
Real time measurements for intracellular Ca2+ concentration were done using 
Ca2+ indicator fura-2/AM (Fig 5.1). 
 
 
 
Fig. 5.1: Structure of Ca2+ 
indicator Fura-2 (C44H47N3O24). 
Its molecular weight is 1001.86 
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Fura-2 can be used to measure intracellular Ca2+ concentration changes for two 
reasons: First, it has an affinity to bind Ca2+ ions in a reversible manner. 
Secondly, the spectroscopic properties of fura-2.Ca2+ complex differ from that of 
the free fura-2. The fluorescence excitation maximum of fura-2 shifts to a lower 
wavelength on Ca2+ binding with negligible shift in the emission maximum. This 
allows fura-2 to be utilized as a dual excitation indicator. For optimal separation 
of fluorescence due to the two forms of the indicator, Ca2+ free fura-2 is usually 
monitored at 380 nm and Ca2+ bound dye at 340 nm. At an excitation wavelength 
of 340 nm, an increase in fluorescence emission indicates an increase in free 
intracellular Ca2+ concentration which can also be measured at an excitation 
wavelength of 380 nm as a decrease in fluorescence emission. Fura-2 has an 
iso-fluorescence point at 360 nm which is useful for monitoring Ca2+ independent 
fluorescence or for following quenching by heavy metal ions (Fig. 5.2).  
 
 
Fig. 5.2: Excitation spectra of Fura-2 solutions with different Ca2+ concentration are shown. 
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Fura-2 is used as an acetoxymethyl (AM) ester form to achieve penetration 
through the lipophilic cell membrane and AM form is then readily activated by 
cellular esterases. Cells were viewed by upright epifluorescence microscope 
using 20X water immersion objective (Fig 5.3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.3: Schematic representation of imaging system. The monochromator sets the wavelength 
sent by the computer via imaging system controller. The monochromatic light is linked to the 
microscope via a specially designed epifluorescence condenser. The fluorescence image is 
detected by a CCD camera. The frame grabber is the interface between the imaging computer 
and the CCD camera. It grabs the digitized images from the camera at 12.5 MHz (12.5 million 
pixels per second). The digitized images are then displayed by the computer as pseudocolor 
images. 
 
 
Monochromator
controller CCD-camera
Light Path
Epifluorescence
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imaging system
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Microscope designed for epifluoroscence allows measurements of fluorescence 
from a region of cells selected specifically by the operator. The microscope 
contains the optical components necessary to deliver the excitation beam to the 
sample, isolate the fluorescence emission signal, and focus it as an image at the 
detector.  
Excitation of the cells was performed at 340 nm and 380 nm and the ratio of the 
emissions was obtained using digital imaging system. Digital fluorescence 
images were acquired and displayed as pseudocolor images and subsequently 
analyzed by choosing defined region of interest so as to exclude any area not 
covered by a cell. Values were acquired at 3 sec intervals at both excitation 
wavelengths (340 and 380 nm). Ca2+ concentration were calculated from 
fluorescence intensities ratio using the following equation (Grynkiewicz et al., 
1985): 
 
     [Ca2+] = Kd [(R - Rmin) / (Rmax – R)] *β 
 
Where, R is the ratio of emission intensity, exciting at 340 nm to emission 
intensity exciting at 380 nm; Rmin is the ratio at zero free Ca2+; Rmax is the ratio at 
saturating Ca2+; β is the ratio of fluorescence intensity exciting at 380 nm for zero 
free Ca2+ to fluorescence intensity exciting at 380 nm at saturating Ca2+. Kd of an 
indicator or chelator is defined as the concentration at which it reaches the half 
saturation point. The dissociation constant (Kd) of Fura-2 is 224 nm. Values for 
Rmin and Rmax were computed using  Ca2+ calibration buffer kit. 
 
Cell loading with Fura-2/AM: 
Fura-2/AM was dissolved in HBSS buffer to 5 µM final concentration containing 
1% BSA to improve solublization of the ester form of the dye and pluronic acid 
(0.08%) to serve as an additional dispersion aid. Cells were grown on glass 
coverslips, precoated with poly-d-lysine (PDL, 1:5). Cells on coverslips were then 
loaded with fura-2 at 37oC for 30 min and then washed 2-3 times with normal 
HBSS buffer before starting the measurements. 
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5.9 In vitro Ca2+ calibration 
Solutions of free Ca2+ concentrations 0 µM and 39 µM were used for calculating 
Rmin and Rmax. These solutions contain 50 µM Ca2+ indicator fura-2. In addition 
the solutions contain 15 µm diameter polystyrene beads in suspension at 16,000 
beads per ml. These beads serve as focusing aid. A third buffer which do not 
contain fura-2 was used as a control to calculate background fluorescence. A 5 µl 
of each solution was pipetted on a clean dry microscope slide. The droplet was 
then covered with  18 x 18 mm coverslips. Using transmitted light polystyrene 
beads in the field of view was focused up and down through until the largest 
diameter was found. After focusing in this plane, the slide was moved on the 
stage to find a field of view without beads visible. A defined area was then 
selected to acquire fluorescence data excited at 340 nm and 380 nm, measuring 
emission at 510 nm. The average of three determinations was made. The 
emission intensity for background fluorescence was corrected by substracting the 
fluorescence value of control buffer (lacking fura-2) obtained at 340 nm excitation 
from each 340 nm excitation value and fluorescence value obtained with 380 nm 
excitation from each 380 nm excitation value. Rmin is the ratio of the emission 
intensity obtained at 340 nm excitation and 380 nm excitation at 0 µM Ca2+. Rmax 
is the ratio of the emission intensity obtained at 340 nm excitation and 380 nm 
excitation at 39 µM Ca2+ (saturating Ca2+).  
 
5.10 Analysis of mitochondrial membrane potential 
Rhodamine-123 was used to monitor the membrane potential of mitochondria. 
The lipohilic nature of rhodamine-123 allows it to diffuse through the 
mitochondrial membrane and accumulate in the mitochondrial matrix in response 
to the electrical gradient. The higher the membrane potential, more is the 
rhodamine-123 taken up into the matrix. Respiring mitochondria generate a 
proton gradient across the inner membrane and this proton gradient was 
assessed by monitoring fluorescence quenching of rhodamine-123. The 
membrane potential can be completely depolarized by an uncoupler like FCCP 
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(carbonyl cyanide 4-trifluoro-methoxyphenylhydrazone), that dissipates the 
potential across the mitochondrial membrane, consequently releasing 
rhodamine-123 producing maximum fluorescence.  
Cells cultured on coverslips, were analyzed for mitochondrial membrane potential 
using the similar microscope and software as described above. Cells were 
loaded with rhodamine-123 at a final concentration of 10 µM in HBSS buffer 
(supplemented with 1% BSA and 0.08% pluronic acid) for 20 min at 37oC, and 
then washed once with normal HBSS buffer. For measurements, cells were 
excited at 470 nm and fluorescence data was acquired at 3 sec intervals. At the 
end of each experiment, mitochondrial membrane potential was completely 
depolarized by FCCP (2 µM) to attain maximal fluorescence. The data presented 
here was normalized to the maximal increase in rhodamine-123 signal in 
response to complete mitochondrial depolarization by FCCP. 
 
5.11 Bioluminescent ATP assay 
ATP was determined luminometrically using ATP bioluminescent somatic cell 
assay kit (Sigma-Aldrich, Germany) according to manufacturer’s protocol. This kit 
is based on the luminometric method employing the luciferin-luciferase reaction. 
This reaction involves the ATP dependent oxidation of luciferin catalyzed by 
firefly luciferase yielding oxyluciferin, AMP, CO2, and pyrophosphate (PPi) as 
products. This is accompanied by emission of light which is linearly related to 
ATP concentration and is measured using luminometer. ATP content was 
measured using internal standards. 
 
5.12 Isolation of mitochondria from cultured cells 
The method for isolation of mitochondria is based on slight modification to the 
method described previously (Schneider et al., 1948). Cells were washed once 
with PBS, trypsinized and pelleted down at 700 x g for 12 min at 4oC. The cell 
pellet was resuspended in 700 µl of RSB buffer and incubated on ice for 10 min. 
The cells were then homogenized on ice in glass teflon homogenizer using 
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20 strokes. This was followed by addition of 700 µl of MS buffer ①  and the 
homogenized cells were pelleted down at 700 x g for 12 min at 4oC. This 
centrifugation step was repeated twice. The pellet contains broken cell 
membranes and nuclei (nuclear pellet). Subsequently, the supernatant (post-
nuclear supernatant) was centrifuged at 16,500 x g for 12 min at 4oC. The pellet 
obtained is the crude mitochondrial fraction ②  (mitochondrial pellet) and the 
supernatant is the post-mitochondrial supernatant. The mitochondrial pellet was 
finally resuspended in 100 µl mixture of RSB and MS buffer (1:1). The nuclear 
pellet, mitochondrial pellet, post-nuclear supernatant and post-mitochondrial 
supernatant were frozen at -80 oC for western blot analysis. 
 
5.13 Bradford method of protein estimation 
Bradford method is a commonly used method for protein estimation (Bradford, 
1976). The method is based on the principle that the absorption maxima of an 
acidic solution of commasive brilliant blue G-250 shifts from 465 nm to 595 nm 
when binding to protein occurs with a concomitant color change from brown to 
blue. 
Serial dilutions of IgG ③  (standard) were prepared starting from 4 µg/µl to 
0.5 µg/µl and 10 µl of samples of unknown protein concentration were taken in 
separate polystyrene cuvettes. 1 ml of bradford reagent was added to both 
samples and standards, mixed well and incubated for 5 min at room temperature. 
The absorbance was taken in spectrophotometer set at 595 nm. Absorbance of 
1 ml bradford reagent without protein was used as a blank and was substracted 
from the absorbance values of both samples and standards. A standard curve 
                                            
① Instead of isotonic sucrose used in the original method, the buffer used consists of mannitol 
and saccharose as described earlier (Bogenhagen and Clayton, 1974). 
②  The crude mitochondrial fraction also consists of ER membranes and golgi membranes. 
Purification of mitochondria, if necessary, can be carried out using discontinuous gradients 
(Magalhaes et al., 1998)  
③ Linear working range of IgG is 125 – 1.5 µg/ml. 
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was later prepared by plotting the blank corrected absorbance values of 
standards vs. its concentration in µg/µl. This standard curve was used to 
determine the protein concentration of each unknown sample. 
 
5.14 Western Blotting 
Cells were cultured to about 80-90% confluency, washed with cold PBS and  
lysed with RIPA lysis buffer. Viscous lysate was sonicated and then mixed with 
laemmli buffer followed by heating at 95oC for 10 min. Samples were then loaded 
on 10-20 % tricine-SDS gels and were allowed to separate at a constant voltage 
of  100 volts. Following this, proteins were electrophoretically transferred to a 
PVDF membrane. The membrane was washed in blocking solution (I-block or 
TBS tween buffer) for 30 minutes on a shaker. Subsequently, the membrane was 
incubated with the primary antibody (diluted in I-block or TBS tween buffer) 
directed against the protein of interest overnight at 4oC, following which the blot 
was washed with I-block buffer three times for 15 min each. The other set of 
same samples were incubated with β-actin, diluted 1:2000, as a control protein. 
The secondary antibody conjugated with alkaline phosphatase was then added 
at 1:5000 dilution and incubated for 1 hour. After the incubation, membrane was 
washed with I-block and developed using the BCIP/NBT④ substrate in alkaline 
phosphatase buffer.  
 
5.15 Preparation of electrocompetent cells 
Bacterial strain, DH5α was inoculated in 5 ml Lurea Bertani (LB) medium 
(preinoculum) and grown overnight at 37oC under constant shaking. 250 ml LB 
medium was inoculated with 75 µl of the preinoculum and grown under constant 
                                            
④ The working principle of this method is that alkaline phosphatase cleaves the phosphatase 
group from BCIP to produce precipitating indoxyl group. This group then dimerizes resulting in the 
reduction of the NBT to produce a dark blue insoluble formazan product. 
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shaking at 37oC until the O.D reaches between 0.6-0.8 at 560 nm. Subsequently, 
the flasks were kept on ice for 15-30 min. The culture was then centrifuged at 
4900 rpm (rotor JLA 10500) at 4oC for 15 min. The pellet was resuspended in 
250 ml of autoclaved cold distilled water and centrifuged at 4900 rpm (rotor JLA 
10500) at 4oC for 15 min. This step of resuspension in water and centrifugation 
was repeated twice in order to wash the cells. The pellet was resuspended in 10 
ml of 10% glycerol and centrifuged again at 4900 rpm (rotor JLA 10500) at 4oC 
for 15 min. The supernatant was discarded and the pellet was finally 
resuspended in 2-3 ml of 10% glycerol. Aliquots were directly frozen in liquid 
nitrogen and later stored at -80oC. 
 
5.16 Electrotransformation 
Electrotransformation is a method of transferring DNA into the bacterial or yeast 
strain by applying high voltage electric field pulses of short duration (Dower et al., 
1988). The electric field pulses create temporary pores in the membrane of the 
cells. These pores are large enough to allow DNA to diffuse into the cells. Upon 
removal of the electric field these pores reseal and the DNA is free to replicate 
and transcribe within the cell. 
The DH5α electrocompetent cells were thawed on ice. A mixture of 80 µl of 
electrocompetent cells and 5 ng of plasmid was transferred to a precooled sterile 
electroporation tube and was then incubated on ice for 20 min. The 
electroporation tube was placed in the electroporator shock pod and a pulse was 
given for few seconds with resistance of 200 ohm, capacitance of 25 µF and 
voltage of 1.6 kV. Following this, 500 µl of SOC medium⑤ was added to it and 
carefully pipetted up and down. The mixture was incubated for 1-2 hrs at 37oC. 
Subsequently, the mixture was centrifuged at 800 x g for 3 min at room 
temperature. The pellet was resuspended in 50 µl of LB medium and was 
                                            
⑤ During electrotransformation, electrolysis of the medium drastically affects the pH which might 
lead to death of many cells if fresh medium is not immediately added for recovery. SOC medium 
works as a recovery medium for bacterial cells. 
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spreaded on LB-agar plates with ampicillin (100 µg/ml) as a selection antibiotic. 
The plates were then incubated overnight at 37oC. 
 
5.17 Plasmid isolation (Midi prep) 
A single colony was picked from the LB-agar plate and inoculated in 2.5 ml of LB 
medium (starter culture) containing the selective antibiotic (ampicillin). The 
culture was incubated for nearly 8 hrs at 37oC with vigorous shaking. The starter 
culture was diluted to 1:500 and 25 ml of selective LB medium was inoculated. 
The culture was grown at 37oC for 12-16 hrs with vigorous shaking. The bacterial 
pellet was harvested at 6000 x g for 15 min at 4oC. The plasmid isolation was 
then carried out using Qiagen plasmid midi kit according to the manufacturer’s 
protocol. The working principle of this kit is based on the modified alkaline lysis 
procedure of plasmid isolation (Birnboim and Doly, 1979). The DNA 
concentration was determined photometrically at 260 nm using 
spectrophotometer. 
 
5.18 Transient transfection 
Transient transfection in HEK293 cells was carried out using Qiagen effectene 
transfection reagent. The working principle of this method is that the DNA is 
condensed by enhancer in a defined buffer system. The subsequent addition of 
effectene reagent spontaneously forms micelles around the condensed DNA. 
Such micelles effectively transfer DNA into the eukaryotic cells.  
Cells were seeded at density of 2x105 per well in 12 well plate, a day before 
transfection. On the day of transfection, 0.3 µg of DNA was diluted with buffer EC 
(condensation buffer) to a total volume of 75 µl. Subsequently, 2.4 µl of enhancer 
was added, mixed and incubated for 5 min at room temperature. 6 µl of effectene 
transfection reagent was then added to DNA-enhancer mixture and incubated for 
10 min at room temperature. Cells were washed with PBS and fresh medium was 
added. Following this, 400 µl of growth medium mixed with transfection complex 
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was immediately added onto the cells. The cells were then incubated under 
normal growth conditions for 48 hrs before analysis. 
 
5.19 Statistical analysis 
Data analysis was performed offline using Microsoft excel 2003. Area under 
curve was calculated using Sigma Plot.7. All results were expressed as mean ± 
SEM. Statistical data was assessed by the unpaired student’s t-test using sigma 
stat 2.03 program. Values less than 0.001 were considered as highly significant 
and values less than 0.05 were considered as significant values. 
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6 Results 
Several studies that have been done till date indicate a link between pathogenic 
mutation in the APP gene and deregulation of Ca2+ homeostasis in AD. To 
identify the cleavage product of APP that is involved in regulating Ca2+ 
homeostasis, basal cytosolic Ca2+ levels and ER Ca2+ content was studied by 
Ca2+ imaging experiments. 
6.1 An enhanced cytosolic concentration of Ca2+ was observed in 
cells lacking APP or its C-terminal cleavage products. 
To elucidate the effect of APP or its cleavage product on basal (or resting) 
cytosolic Ca2+ levels, these levels were analyzed in untransfected wild type 
HEK293 cells (Wt), in HEK293 cells that overexpress APP with Swedish mutation 
⑥ (APPsw) and in HEK293 cells that overexpress wild type APP (wtAPP). These 
cell lines were studied as a model to study effect of cleavage products of APP on 
Ca2+ homeostasis. In addition, similar studies were also done in HEK293 cells 
that co-express APPsw and a dominant negative D385N ⑦  mutation in PS1 
(PSD385N) or in HEK293 cells that co-express APPsw and the gene encoding 
the insulin degrading enzyme ⑧(IDE). These two cell lines (PSD385N and IDE 
expressing) served as a model to study the effect of loss of γ-secretase cleavage 
products of APP on Ca2+ homeostasis. In addition to it, APPsw cells were also 
studied after treatment with the γ-secretase inhibitor, γ-IV⑨.  
Fig. 6.1 shows mean values of Ca2+ measurements by ratiometric imaging using 
fura-2/AM in HEK293 cells. The basal (or resting) cytosolic Ca2+ was calculated 
in the presence of 1.8 mM (physiological Ca2+ concentration) extracellular Ca2+  
                                            
⑥ This mutation dramatically increases β-secretase activity and Aβ42 production (for details see 
page 17). 
⑦  This mutation abolishes γ-secretase activity and therefore has no γ-secretase cleavage 
products of APP. 
⑧ This enzyme efficiently degrades cytoplasmic AICD. 
⑨  This is a peptide aldehyde inhibitor that has been shown to potently inhibit γ-secretase 
cleavage of β-CTF in HEK293 cells expressing APPsw (Sinha and Lieberburg, 1999) 
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from the fluorescence ratio (340/380 nm) of the first 10 cycles (30 sec) (refer fig. 
6.6). 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6.1: Data represented here shows the mean of basal (or resting) cytoplasmic Ca2+ measured 
by fluorescence ratio imaging with fura-2/AM in different stably transfected HEK293 cell lines. 
Cells were loaded with 5 µM fura-2/AM for 30 min at 37oC. Ca2+ ion concentration in individual 
cell was calculated from the 340/380 nm ratio obtained using digital imaging system (for details 
see material and methods). Bars shown in white represents mean values obtained in HEK293 
cells expressing APPsw (APPsw), untransfected HEK293 cells (Wt) and HEK293 cells  
expressing wild type APP (wtAPP). Bars shown in grey represents mean values obtained in 
HEK293 cells co-expressing APPsw and PS1 mutation with a D385N mutation (PSD385N), 
HEK293 cells co-expressing APPsw and the insulin degrading enzyme gene (IDE) and APPsw 
cells treated with γ-secretase inhibitor, γ-IV (10 µM for 24 hours). The statistical significance in 
PSD385N cells, IDE cells or γ-IV treated APPsw cells was determined compared to APPsw cells. 
The figure depicts that basal (or resting) cytosolic Ca2+ level is enhanced as a result of loss of 
APP C-terminal fragments in HEK293 cells. The data represented here is mean ± SEM for 4 to 6 
independent experiments. Number of cells selected for each experiment range between 50 to 80 
cells. Statistical significance **, p < 0.001. 
 
 
Resting cytosolic Ca2+ levels in wild type HEK293 cells (Wt), APPsw cells or 
wtAPP cells exhibited non-significant differences and showed on an average a 
free cytosolic Ca2+ of around 20 nM (Fig. 6.1). On the other hand, PSD385N cells 
exhibited more than four times higher resting cytoplasmic Ca2+ values i.e. 
92 ± 6 nM. Similar observations were obtained in IDE cells (60 ± 4 nM). 
Moreover, HEK293 cells that express APPsw when treated with a potent 
γ-secretase inhibitor, γ-IV (10 µM for 24 hours), also showed an enhanced 
cytosolic Ca2+ levels i.e. 77± 7 nM (Fig. 6.1).  
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In order to prove that the enhanced cytosolic Ca2+ levels observed in PSD385N 
or IDE cells were indeed due to an alteration in production of APP cleavage 
products and not due to other γ-secretase cleavage products, for instance Notch, 
similar measurements were performed in primary cultures of 1-2 days old App 
knockout mouse astrocytes (App0/0) as compared to wild type C57xSv129 
astrocytes (Wt). The mice were routinely genotyped for App0/0 gene before 
measurements. The amplified fragment obtained was around 430 base pairs for 
App0/0 and around 650 base pairs for Wt (Fig. 6.2). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6.2: PCR showing the amplified fragments of App knockout (App0/0) and C57xSv129 mice 
(Wt). The amplified PCR products were separated by 1% agarose gel electrophoresis and was 
obtained about 430 bp for App0/0 and about 650 bp for Wt mice. 
 
 
A significantly enhanced resting Ca2+ levels in App0/0 astrocytes (50 ± 7 nM) as 
compared to Wt astrocytes (30 ± 1 nM) was obtained (Fig. 6.3). Furthermore, to 
evaluate the role of other γ-secretase cleavage products produced for example 
by the two other members of the APP protein family, namely, the amyloid 
precursor like protein 1 and 2 (APLP1 and APLP2), additional experiments were 
performed in the presence of a γ-secretase inhibitor, DAPT⑩. Treatment of App0/0 
                                            
⑩ DAPT is known to acutely lower Aβ and AICD levels (Dovey et al., 2001). 
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astrocytes with γ-secretase inhibitor further enhanced the cytosolic Ca2+ to 
74 ± 7 nM (Fig. 6.3). This experiment indicated that AICD might be the causal 
cleavage product of APP that modulates resting cytosolic Ca2+ levels. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6.3: Data represented here shows basal cytosolic Ca2+ measured by fluorescence ratio 
imaging in fura-2/AM loaded mouse astrocytes. Cytosolic Ca2+ values were calculated from 
340/380 nm ratio obtained during the measurements. Bar shown in white represents mean values 
of basal Ca2+ in wild type C57xSv129 astrocytes (Wt). Bars shown in grey show mean values of 
basal Ca2+ in App knockout astrocytes (App0/0) and App0/0 astrocytes treated with γ-secretase 
inhibitor, DAPT (1µM for 24 hours). App0/0 astrocytes were treated with DAPT in order to exclude 
the effect of AICD produced by APLP1 and APLP2 cleavage. The statistical significance in App0/0 
and App0/0 treated with DAPT was determined compared to Wt astrocytes.The figure depicts that 
cells lacking App exhibit an enhanced basal Ca2+ level which was further enhanced on treatment 
of App0/0 astrocytes with DAPT. The data represented here is mean ± SEM for 6 to 9 independent 
experiments. Number of cells selected for each experiment range between 25 to 35 cells. 
Statistical significance *, p< 0.05 and **, p< 0.001. 
 
 
To ascertain which further γ-secretase cleavage fragment of APP, AICD or Aβ, is 
responsible for modulating the responses observed above, another set of 
experiments were performed to analyze the effects of γ-secretase derived 
intracellular fragment, AICD, using human neuroglioma cells (H4 cells) 
expressing AICD with a VSV tag (AICD-VSV) under the control of  the 
tetracycline inducible promotor (Tet-Off system). Ca2+ imaging experiments were 
made in the cells that express AICD-VSV in the absence of doxycycline 
compared to cells in which its expression was turned off by using doxycycline 
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(Fig. 6.4). These experiments were performed in presence of DAPT (1 µM) to 
exclude any effect of Aβ or AICD produced endogenously.  
 
 
 
 
 
 
 
Fig. 6.4: Western blot showing AICD-VSV protein expression (-Dox) and non-expression (+Dox) 
in H4 cells. Cells were equally plated and cultured for two days in the presence and absence of 
doxycycline (100 ng/ml). Equal volume of lysates was loaded on 10-20% tricine-SDS gel. AICD-
VSV fragment was detected by monoclonal mouse anti-VSV antibody (1:10,000). Equal sample 
loading was analyzed by mouse anti β-actin antibody (1:2000). The AICD-VSV fragment was 
detected at around 7 kDa.  
 
 
As illustrated in fig 6.5, cells lacking AICD-VSV fragments markedly enhanced 
the cytosolic Ca2+ levels to 93 ± 13 nM as compared to AICD-VSV expressing 
cells that showed 28 ± 2 nM of cytosolic Ca2+ levels. This response was 
analogous to the data obtained in the HEK293 cells and in astrocytes. In order to 
confirm that the differences in cytosolic Ca2+ was due to AICD-VSV only and not 
the effect of doxycycline, another control experiment was made under similar 
experimental conditions in H4 cells that express only the regulator plasmid and 
not  the response plasmid (H4-Control). The cells were measured both in 
presence and absence of doxycycline and in the presence of DAPT. There was 
no significant difference in resting cytosolic Ca2+ levels (Fig. 6.5). In order to 
determine the extent of the effect produced by endogenous AICD, H4 cells 
expressing only regulator plasmid were also measured without γ-secretase 
inhibitor (DAPT). In absence of DAPT, H4 cells exhibited resting Ca2+ of 33 ± 6 
nM, a level almost equal to AICD-VSV overexpressing cells (Fig. 6.5). This 
experiment suggests that the endogenous AICD is sufficient to maintain a normal 
Ca2+ balance. The main observation that emerged out of these measurements 
ß-Actin
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was that the ablation of AICD enhances resting cytosolic Ca2+ levels independent 
of the cell types used. 
 
 
 
 
 
 
 
 
 
 
Fig. 6.5: Data illustrated here shows basal cytosolic Ca2+ measured by fluorescence ratio imaging 
in fura-2/AM loaded H4 cells with Tet-off system for AICD and in H4 cells expressing only the 
regulator plasmid for Tet-off system (H4-control). AICD was expressed with a VSV tag (AICD-
VSV). The expression of AICD-VSV was suppressed by administration of doxycycline (100 ng/ml 
for 48 hrs). Both AICD-VSV expressing (-Dox) and non-expressing (+Dox) cells were pretreated 
with DAPT for 24 hrs in order to exclude any effects of endogenous AICD. The data shown here 
for H4-AICD-VSV (+/- Dox) cells is mean ± SEM for 5 to 7 independent experiments. Number of 
cells selected for determination of Ca2+ values range between 40 to 55 cells per experiment. 
Statistical significance *, p < 0.05. H4 cells expressing only the regulator plasmid (H4-control) 
were also measured under similar experimental conditions. To check for the effect of endogenous 
AICD, experiments were also performed in absence of γ-secretase inhibitor, DAPT, in H4-control 
cells. The data represented here for H4-control cells is mean ± SEM for 3 to 4 independent 
experiments and number of cells determined for Ca2+ values were 55 to 65 cells per experiment. 
Statistical significance *,p<0.05 and **, p < 0.001. 
 
 
6.2 ER Ca2+ storage is modulated in cells lacking APP or its C-
terminal cleavage products. 
Inside the cell, Ca2+ load in the cytoplasm is replenished back into the ER 
predominantly by sarco-endoplasmic Ca2+ATPases (SERCA) which work in an 
ATP dependent manner. To investigate if ER Ca2+ level was also affected as a 
consequence of loss of γ-secretase cleavage products of APP, the level of Ca2+ 
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inside the ER was subsequently determined. This was analyzed by the 
application of cyclopiazonic acid (CPA)⑪.  
As shown in fig 6.6 and 6.7, the application of CPA caused a strong rise in 
cytosolic Ca2+ in APPsw cells (570 ± 40 nM) but not in PSD385N mutant cells 
(150  ± 1 nM) (indicated by c). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6.6: Representative traces of Ca2+ measurements in HEK293 cells expressing APPsw 
mutation (left panel) and HEK293 cells co-expressing APPsw with dominant negative D385N 
mutation in PS1 (PSD385N) (right panel). Note the different scales. The horizontal bars indicate 
the time of the application of extracellular fluid with Ca2+ (1.8 mM Ca2+) or without Ca2+ (0 mM 
Ca2+) or cyclopiazonic acid (CPA). Ratiometric images (a-d) show fura-2/AM loaded cells which 
correspond to time points indicated (a-d) in the curve. Scale represents the fluorescence intensity 
of fura-2/AM loaded cells which increases on increase of cytosolic Ca2+. Experiments were 
started when cells were in normal physiological Ca2+ concentration (1.8 mM) in extracellular 
medium (0-60 sec). Values at this time period were taken to calculate resting cytosolic Ca2+ levels. 
Subsequently, extracellular medium with 0 mM Ca2+ was applied. This was followed by addition 
of CPA (10 µM) which causes an increase in cytosolic Ca2+ and then drops down due to buffering. 
The Ca2+ released from ER was calculated as area under the curve. This step was followed by a 
short washing with 0 mM Ca2+ medium and then readdition of 1.8 mM Ca2+. The rise in cytosolic 
Ca2+ by readdition of Ca2+ shows capacitative Ca2+ entry (CCE) and this Ca2+ influx was also 
calculated as area under the curve. The curves represent the mean ± SEM of 75 cells with 
APPsw and 65 cells with PSD385N mutation taken from one single experiment. 
 
                                            
⑪ CPA is known to release Ca2+ from the ER by blocking the Ca2+ATPase present within the ER 
membrane, which maintains a high Ca2+gradient between the cytosol and the ER lumen 
(Schaefer et al., 1994; Mason et al., 1991) 
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In addition to PSD385N mutant cells, a reduced ER Ca2+ release was also 
observed in IDE expressing cells (179 ± 9 nM) and APPsw cells pretreated with 
γ-secretase inhibitor, γ-IV (345 ± 11 nM) as compared to APPsw cells (Fig. 6.7). 
Such reduced ER Ca2+ stores promote the influx of Ca2+ from the extracellular 
medium. This process is termed as capacitative calcium entry (CCE). To show 
further that this is indeed a reduction in the ER Ca2+ levels, CCE was analyzed at 
the end of the experiment by the readdition of 1.8 mM Ca2+ into the extracellular 
medium. Application of 1.8 mM extracellular Ca2+ results in a strong Ca2+ influx in 
PSD385N cells owing to the reduced ER stores as compared to APPsw cells 
(indicated by d in fig. 6.6). Analysis of CCE in IDE expressing cells and APPsw 
cells treated with γ-IV also exhibited the same phenomenon. All these results 
indicated that loss of γ-secretase cleavage products reduce ER Ca2+ storage 
capacity. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6.7: The left panel shows the level of Ca2+ released from the ER on application of CPA 
(10 µM). The Ca2+ values were calculated from the 340/380 nm ratio obtained by Ca2+ imaging of 
fura-2/AM loaded cells. The Ca2+ released from the ER was calculated as area under the curve. 
The right panel shows values for Ca2+ influx by capacitative Ca2+ entry and were also deduced as 
area under the curve. The statistical significance in PSD385N cells, IDE cells or γ-IV treated 
APPsw cells was determined compared to APPsw cells. The figure depicts a lower CPA induced 
ER Ca2+ release and a higher CCE in cells that lack APP C-terminal cleavage products. The data 
represented here is mean ± SEM for 4 to 6 independent experiments. Number of cells selected 
for each experiment range between 50 to 80 cells. Statistical significance *, p< 0.05 and **, 
p<0.001. 
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The reduced ER Ca2+ levels observed above in PSD385N and IDE expressing 
cells could be a consequence of γ-secretase activity on other substrates rather 
than APP. To exclude this possibility and to establish that the effects observed 
were due to APP cleavage product/s only, similar studies were done on primary 
cultures of App0/0 astrocytes. Fig. 6.8 shows representative curves of changes in 
cytosolic Ca2+ levels on different treatments during the course of the 
measurement.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6.8: Representative traces of Ca2+ measurements in primary cultures of Wt astrocytes, 
App0/0 astrocytes and App0/0 astrocytes treated with DAPT (1 µM for 24 hrs). The horizontal bars 
indicate the time of the application of extracellular fluid with Ca2+ (1.8 mM Ca2+) or without Ca2+ 
(0 mM Ca2+) or 10 µM cyclopiazonic acid (CPA). The region indicated by ‘a’ shows the basal 
cytosolic Ca2+ levels in the presence of 1.8 mM extracellular Ca2+, arrow indicated by ‘b’ shows 
the region of CPA induced ER Ca2+ release and the arrow indicated by ‘c’ shows the region of 
capacitative Ca2+ entry on readdition of 1.8 mM Ca2+. The Ca2+ values were deduced from the 
340/380 nm ratio obtained from fura-2/AM loaded cells. The curves represent the mean ± SEM of 
10 cells taken from one single experiment. 
 
 
As shown in fig. 6.8 and 6.9, CPA induced Ca2+ release from intracellular stores 
was found to be reduced in App0/0 (459 ± 12 nM) as compared to control 
astrocytes (532 ± 14 nM). To further evaluate the role of other γ-secretase 
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cleavage products produced by APLP1 and APLP2, similar measurements were 
performed on App0/0 astrocytes pretreated with γ-secretase inhibitor (DAPT). 
Consistent with the results described in HEK293 cells the CPA induced Ca2+ 
release from the ER was further reduced to 364 ± 10 nM as compared to Wt 
astrocytes (Fig 6.9). However CCE on the other hand was not found to be 
significantly affected as compared to the controls (Fig 6.9). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6.9: Bar graph shows CPA induced Ca2+ release from ER (left panel) and CCE on readdition 
of 1.8 mM Ca2+ (right panel) in APP knock out astrocytes (App0/0) compared to Wt astrocytes. In 
addition, App0/0 astrocytes were also analyzed after pretreatment with γ-secretase inhibitor, DAPT 
(1 µM for 24 hours). The data represented here are values of area under the curve for ER Ca2+ 
release by CPA and Ca2+ influx. The data represented here is mean ± SEM for 6 to 9 
independent experiments. Number of cells selected for each experiment range between 25 to 35 
cells. Statistical significance *, p <  0.05. 
 
 
The enhanced cytosolic basal Ca2+ levels and reduced ER Ca2+ release 
observed in IDE expressing HEK293 cells and in App0/0 astrocytes treated with 
DAPT strongly indicated that this phenomenon is attributable to AICD.  
To ascertain that modulation in cellular Ca2+ was due to AICD, HEK293 cells 
expressing PSD385N mutation were transiently cotransfected with cDNA 
encoding AICD together with enhanced green fluorescent protein (pEGFP) as an 
expression control. Ca2+ imaging was performed on the transfected cells 48 hrs 
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later. As shown in fig. 6.10, basal cytosolic Ca2+ was reduced and ER Ca2+ was 
enhanced in cells cotransfected with pEGFP and AICD and also in cells 
transfected with pEGFP alone. These results showed that transfection with 
pEGFP produce non-specific effect on Ca2+ measurements. Therefore this 
strategy could not be followed up further to study the role of AICD on Ca2+. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6.10 Data illustrated here represents the mean values of basal cytosolic Ca2+ (left panel) and 
CPA induced ER Ca2+ release (right panel) in HEK293 cells stably expressing PSD385N and 
transiently cotransfected with pEGFP and AICD constructs. To quantify for the effect of pEGFP 
on Ca2+, PSD385N cells transiently transfected with pEGFP alone were also analyzed as a 
control. Transient transfection was carried out with effectene reagent and Ca2+ imaging was 
performed 48 hrs later. As depicted in the figure, pEGFP transfected and cotransfected cells 
showed a non-significant difference in both basal cytosolic Ca2+ and CPA induced ER Ca2+ 
release, indicating that pEGFP transfection causes non-specific effects on Ca2+ responses. Ca2+ 
values were deduced from the 340/380 nm ratio obtained by Ca2+ imaging of fura-2/AM loaded 
cells. Data shown here is mean ± SEM of 6 experiments per condition. The number of cells 
determined were 40 to 50 cells per experiment. Statistical non-significance , n.s, when p > 0.05. 
 
 
To establish which γ-secretase cleavage product of APP, AICD or Aβ, is 
responsible for reducing ER Ca2+ storage, H4 cells under the control of Tet-Off 
system were analyzed for AICD expression. Experiments for both doxycycline 
treated and non-treated cells were performed in the presence of DAPT to 
exclude the effect of endogenous AICD and Aβ. Fig. 6.11 shows representative 
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curves of changes in cytosolic Ca2+ levels on different treatments during the 
course of the measurement.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6.11: Representative curve of Ca2+ measurements done on H4 cells expressing AICD-VSV 
under the control of Tet-off system. AICD-VSV expression (-Dox) curve is shown in black while 
curve with suppressed AICD-VSV expression (+Dox) is shown in grey. The horizontal bars 
indicate the time of the application of extracellular fluid with Ca2+ (1.8 mM) or without Ca2+ (0 
Ca2+) or CPA (10 µM). The Ca2+ values were calculated from the 340/380 nm ratio obtained from 
Ca2+ imaging of fura-2/AM loaded cells. Each curve represents the mean ± SEM of 40 cells from 
one single experiment. 
 
 
As illustrated in fig 6.11 and 6.12, cells lacking the AICD-VSV fragment (+Dox) 
significantly reduced CPA induced ER Ca2+ release to 312 ± 15 nM as compared 
to cells that express AICD-VSV (-Dox) i.e. 511 ± 40 nM. Furthermore, to prove 
that the reduced CPA induced ER Ca2+ release in doxycycline treated H4 cells 
was not due to any unspecific effect of doxycycline, H4 cells expressing only the 
regulator plasmid (H4-Control) for the Tet-Off system were analyzed. As shown 
in fig 6.12, there was non-significant difference in the CPA induced Ca2+ release 
in both doxycycline treated and untreated cells. All of the experiments described 
above in H4 cells were performed in the presence of DAPT. However, to 
determine the extent of the effect produced by endogenous AICD, additional 
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experiments in H4 cells expressing only regulator plasmid were performed in the 
absence of DAPT. As shown in fig. 6.12, H4-control cells without DAPT 
pretreatment had an enhanced CPA induced ER Ca2+ release to almost 
comparable levels as in AICD-VSV expressing H4 cells. 
These results strongly indicated that the γ-secretase derived C-terminal cleavage 
product of APP, known as AICD, mediates the regulation of resting cytosolic free 
Ca2+ concentration via ER Ca2+ storage. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6.12: Data represented here shows CPA induced ER Ca2+ release both in AICD-VSV 
expressing (-Dox) and non-expressing (+Dox) H4 cells. H4 cells without regulator plasmid 
(H4-Control) were also studied under similar conditions as for H4-AICD-VSV. All cells, where 
indicated, were pretreated with 1 µM DAPT for 24 hrs. Ca2+ values were deduced from the 
340/380 nm ratio obtained from the fura-2/AM loaded cells by Ca2+ imaging. The data shown here 
is the CPA induced Ca2+ release from the ER calculated as area under the curve and is mean ± 
SEM for 3 to 4 independent experiments. The figure depicts that the CPA induced ER Ca2+ 
release is reduced in cells lacking AICD. The number of cells determined were 55 to 65 cells per 
experiment. Statistical significance *, p < 0.05 and **, p<0.001. 
 
 
6.3 Cells lacking AICD have decreased ATP production and 
enhanced mitochondrial membrane potential. 
The above results strongly indicated that the loss of AICD consequently 
enhanced the resting cytosolic Ca2+ levels and reduced ER Ca2+ storage. It can 
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be inferred from the combination of enhanced resting cytosolic Ca2+ and reduced 
ER Ca2+ that Ca2+ removal mechanisms are probably affected as a loss of AICD. 
The removal of resting cytosolic free Ca2+ is tightly regulated and mainly 
controlled by the Ca2+ATPase that is located within the ER membrane. It pumps 
Ca2+ against a strong gradient into the ER lumen in an ATP dependent fashion. 
Maintenance of a normal level of resting Ca2+ therefore is acutely dependent on 
the continuous energy support provided predominantly by mitochondria. 
Therefore, it became relevant to study the efficiency of cell to meet the energy 
demand as a result of the AICD ablation. To assess this hypothesis, direct ATP 
measurements were made using ATP bioluminescent assay. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6.13: Data shown here represents the levels of ATP (nM) per 106 cells represented as 
percentages of the control conditions. ATP levels were calculated using ATP bioluminescent 
assay in H4 cells with suppressed AICD-VSV expression (+Dox) and AICD-VSV expression 
(-Dox). Similar assay was also performed in App0/0 astrocytes and in Wt astrocytes. H4 cells and 
App0/0 astrocytes were pretreated with DAPT (1 µM, 24 hrs). The data represented here is mean 
± SEM for four independent determinations. Statistical significance *, p < 0.05. 
 
 
As shown in fig 6.13, the ATP levels were reduced to 56% in AICD-VSV non-
expressing cells (+Dox) as compared to AICD-VSV expressing cells (-Dox). 
Consistently, App0/0 astrocytes pretreated with DAPT also showed 53% reduced 
ATP generation as compared to Wt astrocytes.  
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As discussed in the preceding text (see introduction), the major factor 
determining the level of mitochondrial ATP production is the mitochondrial 
membrane potential (ψm). In light of the reduced ATP generation found in cells 
lacking AICD, the mitochondrial membrane potential was also analyzed. Here 
this parameter was monitored using rhodamine-123 (Nicholls and Budd, 2000). 
Respiring mitochondria generate a proton gradient across the inner membrane, 
producing a pH gradient and a membrane potential (∆ψm). The membrane 
potential represents most of the energy of the proton gradient. Rhodamine- 
123 is a nerstian dye that distributes itself preferentially across the mitochondrial 
membrane strictly as a function of mitochondrial membrane potential (Nicholls 
and Budd, 2000; Toescu and Verkhratsky, 2000). The lipohilic nature of 
rhodamine-123 allows it to diffuse through the mitochondrial membrane in 
response to potential gradients. The higher the ∆ψm, more is the rhodamine-123 
taken up into the matrix. Carbonyl cyanide 4-trifluoro-methoxyphenylhydrazone 
(FCCP), an uncoupler of oxidative phosphorylation, was used as a control for 
maximal increase in rhodamine-123 fluorescence. FCCP carry protons across 
the inner mitochondrial membrane and causes the mitochondrial membrane 
potential to dissipate. Due to the dissipation of membrane potential, rhodamine-
123 is released from mitochondria producing maximal fluorescence (Fmax).  
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Fig.  6.14: Left panel shows traces of mitochondrial membrane potential studied in H4 cells with 
AICD-VSV expression (-Dox, shown in black) and AICD-VSV non-expression (+Dox, shown in 
grey), pretreated with DAPT (1 µM). The membrane potential shown here is normalized to 
maximal fluorescence on complete depolarization by an uncoupler of oxidative phosphorylation, 
FCCP (Fmax, 1µM), indicated by arrow b. The figure depicts a higher mitochondrial membrane 
potential in cells lacking AICD-VSV. Each trace represents the mean ± SEM of 50 cells from one 
single experiment. Right panel shows fluorescent images of rhodamine-123 (incubated with 
10  µM for 20 min) loaded cells at time points indicated by arrows in the traces. The fluorescence 
values were acquired at 470 nm excitation wavelength at an interval of every 3 sec. The scale in 
the right panel represents fluorescence intensity. 
 
 
As shown in fig. 6.14 and 6.15, the membrane potential was dissipated more on 
FCCP application in AICD-VSV non-expressing cells (+Dox) as compared to 
AICD-VSV expressing (-Dox) H4 cells. Therefore, the F0/Fmax value was lower in 
AICD-VSV non-expressing cells. Similar analysis was also made in App0/0 
astrocytes as compared to Wt astrocytes. As shown in fig. 6.15, consistent with 
the results obtained with H4 cells, dissipation through FCCP was higher in App0/0 
astrocytes as compared to Wt astrocytes. These results imply that the 
mitochondrial membrane is hyperpolarized in cells lacking AICD. 
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Fig. 6.15: Data represented here shows the mean value of the mitochondrial membrane potential 
in H4 cells with (-Dox) or without (+Dox) AICD-VSV expression and in primary cultures of 1-2 
App0/0 astrocytes as compared to Wt astrocytes. All experiments in H4 cells and App0/0 astrocytes 
were performed after pretreatment with γ-secretase inhibitor, DAPT (1 µM for 24 hours). The 
fluorescence values in rhodamine-123 loaded cells were acquired at an interval of 3 sec at 470 
nm excitation wavelength. These values were normalized to maximum fluorescence produced on 
FCCP (1 µM) application and are shown here as F0 / Fmax. The figure depicts that the 
mitochondrial membrane is hyperpolarized in cells lacking AICD. The data represented here is 
mean ± SEM for 4 independent experiments. The number of cells determined were 45 to 55 cells 
per experiment for H4 cells and 25 to 35 cells per experiment for astrocytes. Statistical 
significance *, p < 0.05. 
 
 
6.4 The basal cytosolic free Ca2+ level was enhanced and ER Ca2+ 
was reduced on inhibition of oxidative phosphorylation   
Maintenance of basal cytosolic Ca2+ level is highly dependent upon cytoplasmic 
ATP, either generated by oxidative phosphorylation or glycolysis (Nicholls and 
Budd, 2000; Xiong et al., 2002; Nicholls et al., 2003). Mostly active glycolysis 
suffices to supply ATP in the absence of mitochondrial ATP synthesis. In view 
of the reduced ATP production obtained in cells lacking AICD, the next 
objective was to analyze if the reduced ATP production was indeed due to a 
mitochondrial dysfunction. Also it was aimed to ascertain whether the 
alterations in the Ca2+ homeostasis observed in cells lacking AICD was due to 
a reduced ATP generation. Therefore, pyruvate was substituted for glucose as 
a substrate for the glycolysis, which means that the cells were entirely 
dependent on ATP generation by oxidative phosphorylation. These 
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experiments were performed in AICD-VSV expressing cells and in wild type 
astrocytes. The cells were cultured in glucose depleted conditions for 24 hours 
and the effect of oligomycin (inhibitor of ATP synthase)⑫ and NaCN (inhibitor of 
complex IV) ⑬ was studied. In addition to it, experiments were also performed 
in glucose depleted conditions in order to distinguish between the effect of 
glucose depletion and mitochondrial toxins. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6.16: Left panel, represents the mean values of resting cytosolic Ca2+ in AICD-VSV 
expressing (-Dox) H4 cells on sodium cyanide (inhibitor of complex IV) and oligomycin (inhibitor 
of ATP synthase) treatment. The inhibition by cyanide and oligomycin was studied in cells after 
glucose was substituted with pyruvate for 24 hours to preclude any effect of ATP produced by 
glycolysis. Cells were treated with 10 µM oligomycin for 1 hr and with 2 mM sodium cyanide for 1 
hr in growth medium before measurement. Right panel represents mean values of basal cytosolic 
Ca2+ in AICD-VSV non-expressing cells (+Dox) were also analyzed in order to show that these 
effects were attributable to AICD and not due to non-specific effects of mitochondrial toxins.  Ca2+ 
values were deduced from the 340/380 nm ratio obtained by imaging of fura-2/AM loaded cells. 
Data represented here is mean ± SEM for 3-6 independent experiments. The number of cells 
determined were 40 to 50 cells per experiment for AICD-VSV expressing cells and 60 to 70 cells 
per experiment for AICD-VSV non-expressing cells. Statistical significance *, p < 0.05. 
 
                                            
⑫ Oligomycin prevent the influx of protons through ATP synthase due to which electron transport 
chain ceases to operate and consequently inhibits ATP generation. 
⑬ NaCN inhibits electron flow through the complex IV (cytochrome oxidase) due to which proton 
motive force (or membrane potential) can no longer be sufficiently generated, consequently 
causing inhibition of ATP production. 
0
40
80
120
+Gluc
.
-Gluc. -Gluc. 
Olig.
-Gluc. 
NaCN
+Gluc
.
-Gluc. -Gluc. 
Olig.
-Gluc. 
NaCN
n.s
n.s
n.s
n.s
* *[C
a2
+ ]
 i (
nM
)
Basal H4-AICD-VSV 
(-Dox)
H4-AICD-VSV 
(+Dox)
[C
a2
+ ]
 i (
nM
)
                                                                                                                     Results               
 - 73 -
As shown in fig. 6.16, on treatment of AICD-VSV expressing cells with 
oligomycin and NaCN, the resting cytosolic Ca2+ was enhanced to 47 ± 5 nM 
and 44 ± 4 nM respectively. In addition, in order to ascertain that the Ca2+ 
disturbances were attributable to AICD only and not due to non-specific effects 
of mitochondrial toxins, similar analysis was also made in AICD-VSV 
non-expressing cells (+Dox). A non-significant difference was found on 
treatment of oligomycin, NaCN and glucose depletion in these cells (Fig. 6.16).  
As shown in fig. 6.17, CPA induced ER Ca2+ release on the other hand was 
reduced to 338 ± 16 nM and 288 ± 20 nM in oligomycin and NaCN treated cells 
respectively. Assesment of ER Ca2+ release on similar treatments in AICD-VSV 
non-expressing cells (+Dox) showed non-significant differences (Fig. 6.17). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6.17: The figure represents the mean value of CPA induced ER Ca2+ release in AICD-VSV 
expressing (-Dox) and non-expressing cells (+Dox) on NaCN (10 µM for 1 hr) and 
oligomycin (2 mM for 1 hr) treatment. The cells were grown in glucose depleted medium for 
24 hrs. CPA induced ER Ca2+ release was determined as area under the curve. Ca2+ values were 
deduced from the 340/380 nm ratio obtained by Ca2+ imaging of fura-2/AM loaded cells. Data 
represented here is mean ± SEM for 3-6 independent experiments. The number of cells 
determined were 40 to 50 cells per experiment. Statistical significance *, p < 0.05. 
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However, cells cultured in glucose depleted conditions for 24 hrs showed non-
significant differences in both basal cytosolic Ca2+ levels and CPA induced ER 
Ca2+ release (Fig. 6.16 and 6.17).  
Similar observations were obtained in Wt astrocytes that showed enhanced 
basal cytosolic Ca2+ levels on oligomycin and NaCN treatment i.e. 64 ± 7 nM 
and 51 ± 6 nM respectively as compared to 29 ± 1 nM in non-treated astrocytes 
(Fig 6.18). A reduced CPA induced ER Ca2+ release was also observed in 
oligomycin and NaCN treated Wt astrocytes i.e. 271 ± 7  nM and 345 ± 41 nM 
as compared to non-treated 531 ± 14 nM (Fig. 6.18). However, glucose 
depletion exhibited non-significant differences in resting cytosolic Ca2+ and ER 
Ca2+ release (Fig 6.18).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6.18 The figure represents the mean value of basal cytosolic Ca2+ and CPA induced ER Ca2+ 
release in Wt astrocytes on NaCN (10 µM for 1 hr) and oligomycin (2 mM for 1 hr) treatment. The 
cells were grown in glucose depleted medium for 24 hrs and Ca2+ values were deduced from the 
340/380 nm ratio obtained by imaging of fura-2/AM loaded cells. Data represented here is mean 
± SEM for 4-6 independent experiments. The number of cells determined were 25 to 30 cells per 
experiment. Statistical significance *, p < 0.05 and **, p < 0.001. 
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6.5 Responses of cells lacking AICD were reversed on the 
application of Complex I and II substrates. 
As shown in the above experiments, inhibition of mitochondrial respiratory 
chain mimics the Ca2+ responses from cells lacking AICD or APP. These 
results led to explore if the action of substrates for mitochondrial complexes on 
cells lacking AICD also mimics the phenotype shown by cells expressing AICD. 
To study this, another set of experiment was carried out in which substrates for 
complex I, complex II and complex IV were applied on AICD-VSV non-
expressing cells and App0/0 astrocytes. Citric acid cycle oxidizes different 
substrates and forms electrons carrying high energy compounds i.e. NADH and 
FADH2. NADH and FADH2 are then oxidized by electron transport chain. 
Electrons released by these compounds flow through a series of complexes in 
the electron transport chain (complex I to complex IV) to generate a proton 
gradient across the inner mitochondrial membrane leading to ATP generation. 
As shown in fig. 6.19, substrates for complex I (pyruvate and malate⑭) and 
substrates for complex II (succinate⑮) significantly reduced the basal cytosolic 
Ca2+ levels to 52 ± 1 nM and 40 ± 1 nM as compared to untreated AICD-VSV 
non-expressing (+Dox) cells i.e. 93 ± 13 nM.  However, there was non-significant 
difference in basal Ca2+ levels on treatment with substrates for complex IV 
(TMPD and ascorbate⑯) 
 
 
 
 
 
                                            
⑭ Oxidation of pyruvate and malate in citric acid cycle forms NADH. The electrons of NADH enter 
the oxidative phosphorylation chain at complex I. 
⑮ Oxidation of succinate in citric acid cycle forms FADH2. The electrons of FADH2 enter the 
oxidative phosphorylation chain at complex II. 
⑯ Tetra methyl phenylene diamine (TMPD) is an artificial redox mediator which assists transfer of 
electrons from ascorbate to cytochrome c. 
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Fig. 6.19 Data shown here represents the mean values of basal (or resting) cytosolic Ca2+ 
concentration on treatment of AICD-VSV non-expressing (+Dox) cells. Pyruvate and malate 
(5 mM each for 1 hr in growth medium) was used as a substrate for complex I; methyl succinate 
(10 mM for 1 hr in growth medium) was used as a substrate for complex II; TMPD and 
ascorbate (200 µM and 1 mM respectively for 1 hr in growth medium) was used as a substrate 
for complex IV. AICD-VSV expressing cells (-Dox) were also analyzed in order to show that 
these responses were not due to non-specific effects of mitochondrial substrates. Ca2+ values 
were deduced from 340/380 nm ratio obtained by Ca2+ imaging of fura-2/AM loaded cells. The 
data represented here is mean ± SEM for 4 to 7 independent experiments. The number of cells 
analyzed were 55 to 65 cells per experiment. Statistical significance *, p < 0.05. 
 
 
The CPA induced ER  Ca2+ release was also found to be enhanced by succinate 
treatment to 455 ± 9 nM as compared to untreated AICD-VSV non-expressing 
(+Dox) H4 cells (312 ± 15 nM) (Fig 6.20). However, non-significant reversal was 
seen by the application of complex I and complex IV substrates (Fig 6.20). As a 
control, mitochondrial substrate treatment was also made on AICD-VSV 
expressing cells in order to examine that the application of substrates do not 
produce any non-specific effects. As shown in fig 6.19 and 6.20, a non-significant 
difference was found in these cells on substrate treatment.  
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Fig. 6.20 Data shown here represents the mean values of CPA induced ER Ca2+ release on 
treatment of AICD-VSV non-expressing (+ Dox) and AICD-VSV expressing H4 cells. Pyruvate 
and malate (5 mM each for 1 hr in growth medium) was used as a substrate for complex I; methyl 
succinate (10 mM for 1 hr in growth medium) was used as a substrate for complex II; TMPD and 
ascorbate (200 µM and 1 mM respectively for 1 hr in growth medium) was used as a substrate for 
complex IV. Ca2+ values were deduced from 340/380 nm ratio obtained by Ca2+ imaging of 
fura-2/AM loaded cells. The data represented here is mean ± SEM for 4 to 7 independent 
experiments. The number of cells analyzed were 55 to 65 cells per experiment. Statistical 
significance *, p < 0.05. 
 
 
Similar treatment of substrates were also made on App0/0 astrocytes but only the 
succinate was found to reduce the basal Ca2+ to 56 ± 3 nM as compared to Wt 
astrocytes (74 ± 6 nM) (Fig. 6.21).  The CPA induced Ca2+ release was also 
found to be enhanced to 460 ± 12 nM only by succinate treatment on App0/0 
astrocytes as compared to Wt astrocytes which showed 363 ± 10 nM of CPA 
induced Ca2+ release. Administration of pyruvate and malate (complex I 
substrates) and TMPD (complex IV substrates) on App0/0 astrocytes showed 
non-significant differences in basal cytosolic Ca2+ levels as well as CPA induced 
ER Ca2+ release (Fig. 6.21). 
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Fig 6.21: Left panel represents the mean value of basal cytosolic Ca2+ and right panel represents 
the CPA induced ER Ca2+ release in App0/0 astrocytes on treatment with mitochondrial substrates 
analyzed by Ca2+ imaging. App0/0 astrocytes were treated with pyruvate and malate (5 mM each 
for 1 hr in growth medium) as a substrate for complex I; methyl succinate (10 mM for 1 hr in 
growth medium) as a substrate for complex II; TMPD and ascorbate (200 µM and 1 mM 
respectively for 1 hr in growth medium) as a substrate for complex IV. The data represented here 
is mean ± SEM for 5 to 7 independent experiments. The number of cells analyzed were 35 to 40 
cells per experiment. Statistical significance *, p < 0.05 and **, p < 0.001. 
 
 
 
It is of interest to note here is that the alteration in Ca2+ recovered almost 
completely by substrates of complex II both in H4 cells lacking AICD-VSV and 
in App0/0 astrocytes.  
 
6.6 AICD was not detected in isolated mitochondria. 
To gain insight into the control mechanisms by which AICD might affect 
mitochondrial function, the isolated mitochondria were analyzed for AICD by 
western blotting. As shown in fig. 6.22, no AICD-VSV was not detected in the  
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Fig. 6. 22: Western blot analysis of AICD-VSV in mitochondrial fraction and whole cell lysates 
of AICD-VSV expressing (-Dox) and non-expressing cells (+Dox). Cells were cultured to equal 
confluency under both conditions. Equal volume of mitochondrial fraction and whole cell lysates 
were loaded on 10-20% tricine-SDS gradient gel. AICD-VSV was detected by monoclonal 
anti-VSV antibody (1:10,000). Equal loading of sample was detected by anti-Tim44⑰ antibody 
(1:500). AICD-VSV was detected around 7 kDa and Tim-44 was detected around 42 kDa. 
 
 
crude mitochondrial fraction while it was detected in the whole cell lysates of 
AICD-VSV expressing cells (-Dox). 
 In addition, subcellular fractions were also investigated for AICD-VSV by 
western blotting. As shown in fig. 6.23, a high amount of AICD-VSV was 
detected in nuclear pellet while it was not detected in post-nuclear supernatant 
(PNS) and post-mitochondrial supernatant (PMS). These results indicated that 
AICD is located in nucleus and might affect mitochondrial functioning via 
transcriptional regulation rather than its direct interaction. 
 
                                            
⑰  Transport across the mitochondrial membrane requires translocation machinery. Such 
translocation complex in the inner membrane is called Tim complex (Translocator inner 
membrane) while on the outer membrane is called Tom complex (Translocator outer membrane) 
(Rapaport and Neupert, 1999; Davis et al., 2000) 
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Fig. 6.23: Western blot analysis of subcellular fractions of AICD-VSV expressing (-Dox) and 
non-expressing (+Dox) H4 cells. Protein estimation of each subcellular fraction was done by 
Bradford method and 60 µg protein was loaded on 10-20% tricine-SDS gel. AICD-VSV was 
detected by monoclonal anti-VSV antibody (1:10,000). The AICD-VSV was detected around 
7 kDa. 
 
 
6.7 Responses of cells lacking AICD was reversed on application of 
Li2+ 
A recent study using an inducible expression system reveal that the AICD 
expression modulates expression of GSK-3β (von Rotz et al., 2004). The role of 
AICD in transcription of GSK-3β has also been observed in a study done in 
nuclear extracts of AICD transfected PC12 cells (Kim et al., 2003). Interestingly, 
the active form of GSK-3β has been found in mitochondria (Bijur and Jope, 2003) 
and is known to be an important modulator of mitochondrial function (Hoshi et al., 
1996). Activation of GSK-3β is also known to decrease the transcription of 
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IP3 receptor⑱ genes (Beals et al., 1997; Graef et al., 1999). All these reports 
prompted us to investigate if suppression of AICD modulates Ca2+ homeostasis 
through activation of GSK-3β⑲.  
GSK-3β activity is regulated by its phosphorylation at Ser-9 or Tyr-216 residues. 
Phosphorylation of GSK-3β at Ser-9 position reduces its activity (Plyte et al., 
1992) while phosphorylation at Tyr-216 residues enhances its activity (Hughes et 
al., 1993). Li2+ has been shown to be a direct, reversible inhibitor of GSK-3 with 
an IC50 value of nearly 2 mM (Klein and Melton, 1996), acting as a competitive 
inhibitor of Mg2+ (Ryves and Harwood, 2001). The principle of interaction 
between Li2+ and GSK-3 is that GSK-3 catalyses the phosphorylation of many 
protein substrates in the presence of Mg2+- ATP.  
As shown in fig. 6.24, administration of 5 mM Li2+ for 24 hours on AICD 
non-expressing (+Dox) H4 cells reduce the basal cytosolic Ca2+ levels to 
47 ± 5 nM as compared to untreated cells (93 ± 13 nM). An enhanced CPA 
induced ER Ca2+ release (417 ± 15 nM) was also observed in these cells on 
treatment with 5 mM Li2+. Treatment with 0.5 mM Li2+ and 2 mM Li2+ showed 
non-significant changes both in basal Ca2+ levels and in CPA induced ER Ca2+ 
release. 
 
 
                                            
⑱ Inositol 1,4,5-triphosphate (IP3) receptors are present on the ER membrane, the opening of 
which is regulated by both IP3 and Ca2+. These receptors allow rapid and regulated release of 
Ca2+ from the intracellular stores (Taylor and Laude, 2002). 
 
⑲  Glycogen synthase kinase-3β (GSK-3β) is a serine/threonine kinase that phosphorylates 
glycogen synthase and downregulate its activity. Apart from glycogen synthase, GSK-3β has 
been shown to phosphorylate several other proteins in vitro. These include pyruvate 
dehydrogenase, β-catenin, ATP citrate lyase etc. (Frame and Cohen, 2001). Factors that promote 
cell survival, for instance growth factors, activate Akt which in turn phosphorylates GSK-3β at 
Ser-9, that leads to inactivation of its kinase activity. On the otherhand, mechanisms that promote 
cell death, for instance growth factor removal increase phosphorylation within the catalytic 
domain at Tyr-216 and stimulate kinase activity (Bhat et al., 2000). 
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Fig. 6.24: Left panel shows basal cytosolic Ca2+ levels and right panel shows CPA induced ER 
Ca2+ release in AICD-VSV non-expressing cells (+ Dox) on treatment with LiCl2 for 24 hrs. Cells 
were treated with 0.5, 2 and 5 mM LiCl2 for 24 hrs in growth medium. Ca2+ values were deduced 
from 340/380 nm ratio obtained by fluorescence imaging of fura-2/AM loaded cells. CPA induced 
Ca2+ release is determined as area under the curve. The data represented here is mean ± SEM 
for 6 independent experiments. The number of cells determined were 65 to 75 cells per 
experiment. Statistical significance *, p < 0.05 and **, p < 0.001. 
 
 
In addition, to investigate if GSK-3β expression or its phosphorylation at Tyr216 
is dependent on AICD, the expression for both phosphorylated and total GSK-3β 
was analyzed by western blot in AICD-VSV expressing (-Dox) and non-
expressing (+Dox) H4 cells (Fig. 6.25). As shown in fig 6.25, there were no 
differences observed in expression of both phosphorylated and non-
phosphorylated forms of GSK-3β, indicating that its expression in either form is 
not dependent on AICD.  
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Fig. 6.23: Western blot showing GSK-3β (Upper) and phosphorylated GSK-3β (lower) expression 
in AICD-VSV expressing (-Dox) and non-expressing (+Dox) H4 cells. Cells were equally plated 
and cultured for two days in presence and absence of doxycycline (100 ng/ml). Equal volume of 
lysates was loaded on 10-20% tricine-SDS gel. Total GSK-3β and phosphorylated GSK-3β 
(pY216) was detected by mouse anti GSK-3β and phosphospecific GSK-3β (pY216) antibody 
(1:3000). Equal sample loading was analyzed by mouse anti β-actin antibody (1:2000). The GSK-
3β fragment was detected at around 46 kDa. The band detected above the phosphorylated form 
(pY216) is the double phosphorylated GSK-3β i.e phosphorylated at both pY216 and pS9.  
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7 Discussion 
7.1 AICD regulates cellular Ca2+ homeostasis 
Genetic ablation of the presenilins or pharmacological inhibition of γ-secretase 
activity have been shown to attenuate phosphoinositide mediated Ca2+ signaling 
(Leissring et al., 2002). Such Ca2+ deficits were also observed in cells deficient in 
APP, and these deficits could be rescued by transfection with cDNA encoding 
either full length APP or other C-terminal deletion mutant containing an intact 
AICD domain (Leissring et al., 2002). The results reported in this thesis further 
confirm the critical role of AICD in modulating ER Ca2+ storage. Moreover, this 
work shows for the first time that the resting cytosolic Ca2+ is affected as a 
consequence of loss of AICD in addition to the previously described report which 
shows that ER Ca2+ storage is modulated (Leissring et al., 2002). This 
phenomenon was consistently observed in HEK293 cells that express PS1 with 
the D385N mutation, in HEK293 cells that over express Insulin degrading 
enzyme (IDE) and in HEK293 cells that express APPsw treated with a potent γ-
secretase inhibitor (Wolfe et al., 1999; Kimberly et al., 2000; Edbauer et al., 
2002a). Similar observations were obtained in primary culture of App knock out 
astrocytes (App0/0). As the AICD domain is also produced by the γ-secretase 
cleavage of other APP family members APLP1 and APLP2,  therefore App0/0 
astrocytes were also analyzed in the presence of the γ-secretase inhibitor 
(DAPT) in addition (Scheinfeld et al., 2002). Treatment with DAPT further 
enhanced resting cytosolic Ca2+ levels and reduced CPA induced ER Ca2+ 
transients, strongly indicating the involvement of AICD as a crucial cleavage 
product of APP. Furthermore, to ascertain that the modulation observed in 
resting Ca2+ and ER Ca2+ storage was attributable to AICD, a “Tet-Off” system in 
H4 cells was used for the regulated expression of AICD with a VSV tag 
(AICD-VSV). Consistent with the results obtained in HEK293 cells and in 
astrocytes, strongly enhanced resting cytosolic Ca2+ levels and reduced ER Ca2+ 
release was observed in H4 cells where AICD-VSV expression was suppressed 
by doxycycline. However, H4 cells expressing only the regulator plasmid showed 
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non-significant differences in the resting cytosolic Ca2+ levels in the presence or 
absence of doxycycline, both measured in the presence of DAPT. These cells, 
when analyzed in the absence of DAPT, exhibited normal basal Ca2+ levels and 
CPA induced ER Ca2+ release. This indicates that AICD produced endogenously 
is sufficient to maintain normal resting Ca2+ levels and ER storage. Moreover, 
these results suggest that the alteration of the Ca2+ storage by ER is not merely 
due to the alterations in the mechanism involved in ER Ca2+ release through the 
phosphoinositol cascade (evaluated by bradykinin induced Ca2+ release) as 
suggested previously (Leissring et al., 2002). Our study using CPA mediated 
induction of ER Ca2+ release by inhibiting Ca2+ATPase shows a remarkably 
strong correlation of enhanced resting cytosolic Ca2+ and reduced ER Ca2+ 
release in AICD ablated cells . This supports the idea that there might be an 
alteration in the refilling mechanism of Ca2+ from the cytosol into the ER. In other 
words, these results favor the hypothesis that AICD affects Ca2+ uptake by the 
ER, possibly due to a modulation of activity of the Ca2+ATPase located within the 
ER membrane.  
 
7.2 AICD regulates Ca2+ buffering by ER through mitochondrial ATP 
generation 
Ca2+ removal mechanism including Ca2+ reuptake by the ER from the cytosol is 
predominantly dependent on the ATP generation by mitochondria. To account for 
an enhanced cytosolic Ca2+ in cells lacking AICD, a direct measurement of ATP 
was carried out using bioluminescent ATP assay. This assay revealed that 
AICD-VSV non-expressing H4 cells and App0/0 generate significantly lower 
amounts of ATP.  
To confirm the hypothesis that the Ca2+ disturbances seen in cells lacking AICD  
are due to lower ATP generation, another set of experiments were carried out in 
which AICD-VSV expressing cells and wild type astrocytes were treated with 
oligomycin and sodium cyanide (NaCN). Both the conditions inhibit ATP 
generation. Oligomycin inhibits ATP synthase and NaCN inhibits electron 
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transport through complex IV (cytochrome oxidase). Altering mitochondrial 
function by oligomycin and NaCN was found to alter the Ca2+ homeostasis in a 
similar manner as the depletion of AICD. However lack of AICD was found to 
have a stronger effect on the Ca2+ homeostasis than the total inhibition of 
mitochondrial function. This may be due to the fact that the action of the 
mitochondrial blocker was analyzed after an interval of one hour whereas the 
effect of a downregulation of AICD expression was analyzed after 48 hours.  
Since cellular ATP generation is driven by mitochondrial membrane potential, 
therefore it was also analyzed in both AICD expressing H4 cells and in astrocytes. 
It was found that H4 cells that do not express AICD-VSV (+Dox) and App0/0 
exhibited a higher membrane potential or in other words the mitochondrial 
membrane was hyperpolarized. One possible explanation for this phenomenon is 
that the ATP synthase activity is reduced as a consequence of lack of AICD. A 
reduced ATP synthase activity and hyperpolarized mitochondrial membrane is a 
condition analogous to inhibition of ATP synthase by oligomycin. Oligomycin 
inhibits flow of protons through F0 particle of ATP synthase eventually increasing 
mitochondrial membrane potential (Baracca et al., 2003).  
Another point worth noting is that the application of substrate for complex II i.e. 
succinate efficiently normalizes Ca2+ disturbances. In general, substrates for 
complex II generate a significantly higher membrane potential than substrates for 
complex I (Nicholls, 1974). Complex II, also called succinate dehydrogenase, is 
the only enzyme of the respiratory complex that functions in two ways, one as a 
part of electron transport chain and second as a component of citric acid cycle. It 
oxidizes succinate to fumarate and generates FADH2, which serves to feed 
electrons to the respiratory chain. Application of high amounts of succinate might 
therefore enforce the ATP synthase to function in direction of ATP synthesis by 
further increasing mitochondrial membrane potential. However, further studies 
are required to reveal if lack of AICD indeed affects the mitochondrial ATP 
synthase.  
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7.3 AICD might regulate Ca2+ homeostasis and mitochondrial 
function through gene transcription. 
AICD being a highly labile product of APP have been shown to be stabilized by 
binding of nuclear adaptor protein, Fe65 and translocate to nucleus. Fe65, in turn, 
interacts with the transcription factors CP2/LSF/LBP1 and a histone 
acetyltransferase, Tip60 (Fiore et al., 1995; Cao and Sudhof, 2001; Kimberly et 
al., 2001; Minopoli et al., 2001; Walsh et al., 2003). AICD complexed with Fe65 
and Tip60 has been shown to potently regulate the expression of artificial 
expression constructs (minigenes) in transfected cells (Cao and Sudhof, 2001). 
There could be several possible mechanisms by which AICD might modulate 
Ca2+ signaling and mitochondrial function. Numerous compelling evidences 
about the role of AICD in gene transcription add support to the hypothesis that 
AICD might affect Ca2+ signaling by regulating the expression of genes involved 
in Ca2+ homeostasis and energy production. Leissring et al. suggested that 
CP2/LSF/LBP1 response elements are present in the regulatory region of an ER 
Ca2+ATPase, as revealed by BLAST search (Leissring et al., 2002). AICD has 
also been shown to induce the expression of GSK-3β at both mRNA and protein 
levels in neuronal cells (Kim et al., 2003). The active form of GSK-3β is also 
known to be an important modulator of mitochondrial function (Hoshi et al., 1996). 
To our surprise, administration of 5 mM Li2+ (a reversible inhibitor of GSK-3) for 
24 hrs lowered the resting cytosolic Ca2+ levels and elevated the ER Ca2+ release 
in AICD-VSV non-expressing cells. However, in contrast to the results described 
by Kim et al., we found no differences both in total levels of GSK-3β and active 
form of GSK-3β (phosphorylated at Tyr216), between AICD-VSV expressing 
(-Dox) and non-expressing (+Dox) H4 cells at protein levels. This indicates that 
Li2+ produces a downstream effect that normalizes the resting cytosolic Ca2+ and 
ER Ca2+ release in cells lacking AICD, independent of GSK-3β.  
Cloning and sequencing the APP gene revealed a -GYENPTY- motif in the 
cytoplasmic tail. Multiple sequence alignment of the cytoplasmic tail of APP 
reveals that only the -GYENPTY- motif is 100% conserved from C.elegans to 
human, suggesting a significant role of this domain. Subsequent mutational 
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analysis defined the -YENP- sequence as the critical tetrapeptide motif for APP 
internalization (Perez et al., 1999). The -GYENPTY- sequence is also a 
consensus motif for the binding of adaptor proteins that possess a 
phosphotyrosine binding (PTB) domain, such as those in the Fe65, X11 and JIP 
families. A recent report provides strong evidence in favour of nuclear signaling 
functions of AICD and shows that these functions are regulated by the APP 
adaptor proteins Fe65, Jip1b and X11-α as well as the nuclear docking protein 
Tip60. This report also shows that AICD regulates the expression of APP gene in 
a positive feedback mechanism. In otherwords, endoproteolysis of APP 
upregulates its own expression eventually replenishing full length APP (von Rotz 
et al., 2004).  It has also been reported that Fe65 on binding with the NPTY 
domain of AICD interacts with Mena (Ermekova et al., 1997). Mena is a 
cytoskeletal protein involved in microfilament assembly and cell motility. It is also 
found in areas of dynamic actin remodeling such as axonal growth cones (Gertler 
et al., 1996). Interestingly, hippocampal neurons derived from App knockout mice 
have reduced neuritic branching and outgrowth (Perez et al., 1997), suggesting 
an involvement of the APP/Fe65/Mena protein complex. In addition, the 
cytoplasmic domain of APP (AICD) interacts with other adaptor proteins like X11, 
BP1 (APP binding protein 1), ShcA (SH2 domain containing transforming protein 
1), SHcC, PAT1 (protein that interacts with APP tail 1), JNK interacting protein, 
and disabled 1 (Fiore et al., 1995; Chow et al., 1996; Borg et al., 1996; 
Tanahashi and Tabira, 1999; Homayouni et al., 1999; Gao and Pimplikar, 2001; 
Matsuda et al., 2001). All of these evidences suggest a critical role for AICD in 
gene regulation and intracellular signaling pathways.  
However, identifying which genes are regulated by AICD is another major 
question of future research. In view of AICD controlling gene expression, it is 
possible to envision that signaling through APP could influence Ca2+ dependent 
processes such as cellular differentiation, neurite outgrowth and synaptic 
plasticity.  
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7.4 AICD might regulate mitochondrial function directly 
In support of direct interaction of AICD with mitochondria, recent reports indicate 
the location of APP, its cleavage and its degradation components in mitochondria. 
Full length APP has been shown to be targeted to the mitochondria in a 
transmembrane arrested topology in neuronal cells. The C-terminal domain of 
APP faces the cytoplasmic side and causes the transmembrane arrest. The 
transmembrane arrested APP is either in direct contact with, or traversing 
through the TOM40 translocase (a translocator of mitochondrial protein) 
(Anandatheerthavarada et al., 2003). In addition to APP, active γ-secretase 
complex and IDE are also reported to be present in mitochondria (Leissring et al., 
2004; Hansson et al., 2004). On the contrary, our study in subcellular fractions in 
AICD-VSV expression system indicates that AICD is not present in mitochondria. 
Its detection in nuclear pellet supports the previously described report indicating 
its role in gene transcription (Cao and Sudhof, 2001). Whether or not AICD 
regulates mitochondrial function by transcriptional regulation needs to be further 
investigated. Since all components i.e. APP, active γ-secretase complex and IDE 
have been shown to be present in the mitochondria, one cannot completely rule 
out the possibility of its direct involvement. 
 
7.5 AICD and Alzheimer’s Disease 
Alzheimer’s disease is characterized by synaptic dysfunction and excitotoxicity 
leading to the death of neurons. Several evidences suggest that these 
neurodegenerative processes involve mechanisms that alter cellular Ca2+ 
homeostasis (Harkany et al., 2000). Mitochondrial based energy deficits have 
also been implicated in the pathophysiology of AD (Sullivan and Brown, 2005).  
It is a well described fact that pathogenic mutations in presenilin, which cause 
FAD enhance the production of the highly amyloidogenic Aβ42. FAD mutations in 
PS1 have also been shown to modulate Ca2+ signaling in a variety of systems, 
including fibroblasts from FAD patients, mutant presenilin “knock in“ mice, 
transgenic mice, transfected PC12 cells and xenopus oocyte (Ito et al., 1994; 
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Guo et al., 1996; Guo et al., 1997; Gibson et al., 1997; Etcheberrigaray et al., 
1998; Begley et al., 1999; Leissring et al., 1999b; Guo et al., 1999b; Herms et al., 
2003). A report by Chen et al. shows that although presenilin mutations augment 
γ-secretase cleavage at residue 42 (generating Aβ42), they infact suppress 
ε-cleavage ⑳ of APP generating AICD (Chen et al., 2002). This report supports 
the notion that PS1 mutation causing early onset of familial Alzheimer’s disease 
(EOFAD) and disturbances in Ca2+ homeostasis might be a consequence of loss 
of AICD. An increased BACE1 (β-secretase) expression and activity has also 
been shown in the sporadic AD brain (Holsinger et al., 2002; Yang et al., 2003). 
Recently it has been shown that elevated β-secretase (BACE) levels induced the 
increase of C99 and Aβ generation but reduced C83 and AICD generation in vitro 
(Kume et al., 2004). These reports link decreased AICD levels also to sporadic 
AD. All these evidences lead to speculate that AICD might be the underlying 
cleavage product of APP, suppression of which cause cellular disturbances in AD. 
In addition to Ca2+ disturbances found in AD, the disease is also characterized by 
mitochondrial defect and deficits in energy production. Our results revealed that 
AICD-VSV non-expressing cells (+Dox) and App0/0 astrocytes exhibits 56% and 
53% reduced ATP generation, respectively, as evaluated by bioluminescent ATP 
assay. These results link to a previously described report by Hoyer et al. showing 
a decrease in ATP production from glucose by around 50% in the first stages of 
sporadic AD. The oxidative utilization of substrates other than glucose restores 
ATP formation to 80% of normal, but thereafter ATP levels decrease throughout 
the course of the disease (Hoyer, 1992). A fall in ATP formation in the sporadic 
AD brain has also been demonstrated by other investigators (Sims et al., 1983b; 
Brown et al., 1989). This energy deficit may compromise ATP dependent 
processes. For instance, a depletion of cellular ATP levels prevents the 
dissociation of chaperons/protein complexes and thus blocks secretion of these 
                                            
⑳ Weidemann et al. have referred to the cleavages of APP C-terminal domain at residues 40-42 
as γ-secretase cleavage and the cleavages at residues 49-52 as ε-cleavage (Wiedemann et al., 
2002). The authors Chen et al. have retained the same terminology. However, the relation 
between γ- and ε-cleavage is unknown till date. 
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proteins (Dorner et al., 1990). Misfolded or malfolded protein complexes 
accumulate in the ER and are indicative of “endoplasmatic reticulum stress” 
(Kaufman, 1999). Alternatively, deficits in ATP production due to the loss of AICD 
can be transiently balanced by the cell by the utilization of endogenous 
substrates like amino acids and fatty acids to meet the energy demand. However, 
it has been described earlier that in EOFAD, glucoplastic amino acids, in 
particular glutamate, are used for energy formation to maintain ATP 
concentrations at a normal level. As a side effect of glutamate utilization, 
neurotoxic ammonia is formed in the brain and inhibits mitochondrial 
dehydrogenases such as α-ketoglutarate dehydrogenase, isocitrate 
dehydrogenase and malate dehydrogenase (Hoyer et al., 1990; Lai and Cooper, 
1991). In addition to this, a reduced activity of pyruvate dehydrogenase (the 
enzyme that converts pyruvate to acetyl-CoA in mitochondria) has been found in 
the brain of AD patients (Perry et al., 1980; Sorbi et al., 1983). This effect can be 
related to other major symptoms of AD, as reduced pyruvate dehydrogenase 
activity results in a decreased level of acetyl-CoA, and together with a diminished 
activity of choline acetyl transferase, the synthesis of acetylcholine in the 
presynaptic neuron is markedly reduced (Sims et al., 1983a). In this respect, it is 
noteworthy that the degradation of the cholinergic system correlates with the 
progression of mental disturbances in patients with AD (Baskin et al., 1999). A 
decreased concentration of acetyl-CoA may also decrease the formation of 
intracellular cholesterol (Michikawa and Yanagisawa, 1999). Cholesterol is the 
main sterol in membranes and is important for the normal cell function. 
Cholesterol levels are markedly decreased in brain membranes and in the 
cerebrospinal fluid (CSF) of patients with AD (Svennerholm and Gottfries, 1994; 
Mulder et al., 1998; Eckert et al., 2000). Another study done in brain samples of 
AD patients shows a 50%-60% decrease in mRNA levels of nuclear DNA that 
encodes subunit IV of cytochrome oxidase and the beta-subunit of the F0F1-ATP 
synthase (Chandrasekaran et al., 1997). 
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Based on earlier studies described in the discussion and the results obtained in 
this thesis work, a hypothetical model is drawn that illustrate a possible link of 
reduced AICD generation to AD (Fig. 7.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 7.1: Hypothetical model of the etiological role of AICD in AD. Both familial and sporadic forms 
of AD have been shown to produce decreased levels of AICD. Suppression of AICD leads to 
disturbed Ca2+ homeostasis which is proposed to be due to mitochondrial dysfunction and deficits 
in ATP production. Progress of sporadic AD leads to reduced ATP levels either due to decreased 
activity of pyruvate dehydrogenase (PDH) or decrease in the activity of other enzymes of the citric 
acid cycle. Reduced ATP generation through oxidation of glucose leads to oxidation of non-
carbohydrate precursors as an alternate source of ATP. Oxidation of amino acids produce toxic 
ammonia which also reduces enzymatic activity of citric acid cycle enzymes. The energy deficits 
due to mitochondrial dysfunction might lead to perturbances in Ca2+ homeostasis. AICD also 
regulates the expression of APP in a positive feedback mechanism and might lead to enhanced 
production of Aβ42 in diseased condition. Alternatively, AICD might transcriptionally regulate 
certain genes that are vital for mitochondrial functioning and Ca2+ homeostasis.   
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7.6 Consequences of gamma secretase inhibitors as therapeutic 
drug targets for Alzheimer’s disease 
The existence of pathogenic mutations in APP and PS genes provides a strong 
support that Aβ production and deposition contribute to the etiology of AD. The 
most direct approach to reduce the amyloid levels is to control the production by 
inhibiting γ-secretase that liberates the Aβ peptide from the precursor. It should 
be noted that γ-secretase appears to have more substrates and cleavage 
products, for instance the production of AICD besides producing Aβ. Studies 
done in this thesis work implicate an important function of AICD in maintaining 
cellular Ca2+ homeostasis and energy production. Therefore, discovery of drugs 
that can selectively inhibit Aβ without disrupting the production of AICD or inhibit 
the generation of Aβ42 rather than Aβ40 needs to be developed. 
In the light of these functions of AICD and the universal importance of Ca2+ as the 
major intracellular signaling cation, the therapeutic use of γ-secretase inhibitors 
for prevention of AD needs to be carefully evaluated. 
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